Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis

ABSTRACT

Useful chiral specific boron-containing compounds, such as boronate, boronate esters, boranamines, borane diamines, boranamine thioesters, and boronic mono/di-thioesters, have been prepared. These compounds and compositions containing them are useful as anti-cancer or anti-amyloidosis agents.

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. patent application Ser. No. 16/204,066, filed Nov. 29, 2018, which is a continuation of U.S. patent application Ser. No. 15/186,988, filed Jun. 20, 2016 and now U.S. Pat. No. 10,144,761, which claims the benefit of U.S. Provisional Application Ser. No. 62/181,910, filed Jun. 19, 2015. The entire contents of each of the aforementioned applications are incorporated herein by reference.

FIELD OF THE INVENTION

The invention herein is directed to chiral specific boron-containing compounds, such as boronate, boronate esters, boranamines, boranediamines, boranamine thioesters, and boronic mono/di-thioesters, as anti-cancer or anti-amyloidosis agents, as well as their compositions, methods of preparation, and methods of treatment.

BACKGROUND OF THE INVENTION

It is known that some peptide boronic acid compounds are proteasome inhibitors, and they represent an important strategy in cancer therapy. Besides the marketed drug VELCADE® (Bortezomib or chemical name as [(1R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2[(pyrazinylcarbonyl)amino]propyl]amino]butyl] boronic acid) for the treatment of multiple myeloma, other types of cancers, and amyloidosis. There are a number of structurally different peptide boronic acids at various stages of clinical trials. One major issue of this group of boronic acids as (active pharmaceutical ingredient (API) is that they are not very stable at ambient conditions. The drug VELCADE®, for example, needs to be stored at below ambient temperature and kept away from light. Partially related to its instability, the drug VELCADE® is formulated as an injection mixture, and patients must go to doctors' offices or hospitals for drug administration. Boronic acids are known to form many boronic acid derivatives, such as boronates and boronate esters. Boronates and boronate esters are able to be converted back to boronic acid under certain conditions.

The present invention describes a group of boron-containing compounds, such as boronate, boronate esters, boranamines, boranediamines, boranamine thioesters, and boronic mono/di-thioesters, that are stable at ambient conditions. They can be formulated as both liquid and solid drugs. Therefore, the bioactive component of the drug can be circulated longer in the human body and reach more areas unavailable to the direct injection into blood vessels.

DEFINITION OF TERMS

Unless otherwise explicitly stated, R is intended to refer an aliphatic or aromatic group.

Unless otherwise explicitly stated, the term “aliphatic” or “aliphatic group” is intended to refer a substituted or unsubstituted straight-chain, branched or cyclic C₁-C₁₂ hydrocarbon, which is completely saturated or which contains one or more units of unsaturation, but which is not aromatic. Aliphatic group also includes atoms other than C in the backbone, such as, but not limited to, N, S, and O. Aliphatic group also includes one or more functional groups attached to the backbone, such as, but not limited to, —OH, —SH, —CO—OH, —CO—OR (ester), —NH₂, —NHR, —CO—R (ketone), —O—SO₂ (sulfonate), —NH—SO₂ (sulfonamide) and —NR—SO₂ (sulfonamide).

Unless otherwise explicitly stated, the term “aromatic” or “aromatic group” is intended to refer a substituted or unsubstituted planar unsaturated ring of atoms that is stabilized by an interaction of the bonds forming the ring. Atoms forming an aromatic group include, but are not limited to, C, O, S, and N.

Unless otherwise explicitly stated, the term “peptide” is intended to refer to a short chain of amino acid monomers linked by amide (—NH—CO— or —NR—CO—) bonds. R represents an aliphatic or aromatic group. Each C atom in the amino acid monomer may have one or two substitution groups, and the substitution groups are aliphatic, aromatic or both aliphatic and aromatic. The covalent chemical bonds are formed when the carboxyl group of one amino acid reacts with the amino group of another.

Unless otherwise explicitly stated, the term “backbone” is intended to refer to the longest hydrocarbon chain in a molecule or a group. It also refers to the longest hydrocarbon chain with other atoms in the chain, such as, but not limited to, O, S, and N, in a molecule or a group.

Boronate, boronate esters, boranamines, boranediamines, boranamine thioesters and boronic mono/di-thioesters are illustrated by the corresponding general structures showed below.

In the compounds of this invention any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise stated, when a position is designated specifically as “H” or “hydrogen”, the position is understood to have hydrogen at its natural abundance isotopic composition. Also, unless otherwise stated, when a position is designated specifically as “D” or “deuterium”, the position is understood to have deuterium at an abundance that is at least 3000 times greater than the natural abundance of deuterium, which is 0.015% (i.e., at least 45% incorporation of deuterium).

SUMMARY OF THE INVENTION

The present invention provides novel boron-containing compounds and stable pharmaceutically acceptable compositions comprising them. These compounds are useful in treatment of diseases, such as cancers, cancerous conditions, plaque, or a plaque-forming condition such as amyloidosis, in a human or warm-blooded animal or mammal.

In one aspect of the invention, compounds of the general formula (I), or pharmaceutically acceptable salts thereof, are provided:

wherein:

Z₃ is a peptide containing 1-20 amide bonds and the boron atom in formula (I) attaches to a C atom, not an N atom nor —C═O;

Z₁ and Z₂ are structurally the same or different side chains attached to boron atom in the formula (I);

Z₁ and Z₂ are each represented by the formula: —X—R₁   Formula (II) wherein:

X is O, S, NH, NR, —O—CO, —NH—CO, —NR—CO, —SO₂, —NH—SO₂, or —NR—SO₂, R being an aliphatic or aromatic substitution group; and

R₁ is an aliphatic chain with C₁-C₂₀ hydrocarbon; R₁ also represents an aliphatic chain with C₁-C₂₀ hydrocarbon which has one or more X in the backbone; R₁ also represents an aliphatic chain with C₁-C₂₀ hydrocarbon which has one or more aliphatic, aromatic, or both aliphatic and aromatic substitution groups on the backbone.

In another aspect of the invention, compounds of the general formula (III), or pharmaceutically acceptable salts thereof, are provided:

wherein:

Z₃ is a peptide containing 1-20 amide bonds and the boron atom attaches in formula (III) to a C atom, not an N atom nor —C═O;

Z₄ and Z₅ each attach to the boron atom in the formula (III) and also join together on the other end to form a ring;

the ring formed by joining Z₄ and Z₅ together with boron is represented by formula (IV):

the ring size counting all atoms on the backbone of the ring in formula (IV) is 4-20 atoms; and

the backbone of the compound in formula (IV) constructed with atoms such as, but not limited to, B, C, O, S, and N:

wherein:

X₁ and X₂ in formula (IV) are atoms or links or linkers, and they are the same or different;

X₁ is O, S, NH, NR, —O—CO, —NH—CO, —NR—CO, —O—SO₂, —NH—SO₂, or —NR—SO₂;

X₂ is O, S, NH, NR, —O—CO, —NH—CO, —NR—CO, —O—SO₂, —NH—SO₂, or —NR—SO₂;

R is an aliphatic or aromatic substitution group; and

R₂ in formula (IV) represents the rest of the backbone of the ring besides B, X₁, and X₂: R₂ also represents an aliphatic chain with C₁-C₂₀ hydrocarbon which has one or more X₁ or X₂ in the backbone; R₂ also represents an aliphatic chain with C₁-C₂₀ hydrocarbon which has one or more aliphatic, aromatic, or both aliphatic and aromatic substitution groups on the backbone.

In some cases, two substitutions on the backbone of R₂ also form another ring A which is illustrated by formula (V):

wherein:

the size of ring A in formula (V) is 3-10 atoms; and

Ring A in formula (V) is constructed by atoms such as, but not limited to, C, O, S, or N.

In another aspect of the invention, compounds of the general formula (VI), or pharmaceutically acceptable salts thereof, are provided:

wherein:

Z₃ is a peptide containing 1-20 amide bonds and each boron atom attaches to a C atom, not an N atom nor —C═O;

Rings B and C are the same or different;

Rings B and C have the same descriptions as compounds represented by formula (III);

X₃ is O, S, NH, NR, —O—CO, —NH—CO, —NR—CO, —O—SO₂, —NH—SO₂, or —NR—SO₂;

X₄ is O, S, NH, NR, O—CO, —NH—CO, —NR—CO, —O—SO₂, —NH—SO₂, or —NR—SO₂;

X₅ is O, S, NH, NR, —O—CO, —NH—CO, —NR—CO, —O—SO₂, —NH—SO₂, or —NR—SO₂;

X₆ is O, S, NH, NR, —O—CO, —NH—CO, —NR—CO, —O—SO₂, —NH—SO₂, or —NR—SO₂;

R is an aliphatic or aromatic substitution group;

Rings B and C in compounds represented by formula (VI) are connected by link or linker R₃;

In compounds represented by formula (VI), link or linker R₃ connects with X₇ in ring B and X₈ in ring C;

In compounds represented by formula (VI), X₇ is C, N, or other atoms or groups that can form three bonds; X₈ is C, N, or other atoms or group that can form three bonds; and

In compounds represented by formula (VI), R₃ represents an aliphatic chain with C₁-C₁₀ hydrocarbon; R₃ also represents an aliphatic chain with C₁-C₁₀ hydrocarbon which has one or more other atoms such as, but not limited to, O, S, or N in the backbone; R₃ also represents an aliphatic chain with C₁-C₁₀ hydrocarbon which has one or more aliphatic, aromatic, or both aliphatic and aromatic substitution groups on the backbone.

In another aspect of the invention, compounds of the general formula (VII), or pharmaceutically acceptable salts thereof, are provided:

wherein:

Z₃ is a peptide containing 1-20 amide bonds and boron atom attaches to a C atom, not N atom nor —C═O;

Ring D in formula (VII) has two boron atoms;

the size of ring D counting for all atoms in the backbone of the ring in formula (VII) is 6-20 atoms;

X₉, X₁₀, X₁₁, and X₁₂ in formula (VII) are the same or different;

X₉ is O, S, NH, NR, —O—CO, —NH—CO, —NR—CO, —O—SO₂, —NH—SO₂, or —NR—SO₂;

X₁₀ is O, S, NH, NR, —O—CO, —NH—CO, —NR—CO, —O—SO₂, —NH—SO₂, or —NR—SO₂;

X₁₁ is O, S, NH, NR, —O—CO, —NH—CO, —NR—CO, —O—SO₂, —NH—SO₂, or —NR—SO₂;

X₁₂ is O, S, NH, NR, —O—CO, —NH—CO, —NR—CO, —O—SO₂, —NH—SO₂, or —NR—SO₂;

R is an aliphatic or aromatic substitution group;

R₄ and R₅ in formula (VII) are the same or different;

In compounds represented by formula (VII), R₄ represents an aliphatic chain with C₁-C₁₀ hydrocarbon; R₄ also represents an aliphatic chain with C₁-C₁₀ hydrocarbon which has one or more other atoms such as, but not limited to, O, S, or N in the backbone; R₄ also represents an aliphatic chain with C₁-C₁₀ hydrocarbon which has one or more aliphatic, aromatic, or both aliphatic and aromatic substitution groups on the backbone; and

In compounds represented by formula (VII), R₅ represents an aliphatic chain with C₁-C₁₀ hydrocarbon; R₅ also represents an aliphatic chain with C₁-C₁₀ hydrocarbon which has one or more other atoms such as, but not limited to, O, S, or N in the backbone; R₅ also represents an aliphatic chain with C₁-C₁₀ hydrocarbon which has one or more aliphatic, aromatic, or both aliphatic and aromatic substitution groups on the backbone.

In another aspect of the invention, compounds of the general formula (VIII), or pharmaceutically acceptable salts or thereof, are provided:

wherein:

Z₃ is a peptide containing 1-20 amide bonds and each boron atom attaches to a C atom, not an N atom nor —C═O;

Ring E in formula (VIII) has three boron atoms;

the size of ring E counting for all atoms in the backbone of the ring in formula (VII) is 9-20 atoms;

X₁₃, X₁₄, X₁₅, X₁₆, X₁₇, and X₁₈ in formula (VII) are the same or different;

X₁₃ is O, S, NH, NR, —O—CO, —NH—CO, —NR—CO, —O—SO₂, —NH—SO₂, or —NR—S₂;

X₁₄ is O, S, NH, NR, —O—CO, —NH—CO, —NR—CO, —O—SO₂, —NH—SO₂, or —NR—SO₂;

X₁₅ is O, S, NH, NR, —O—CO, —NH—CO, —NR—CO, —O—SO₂, —NH—SO₂, or —NR—SO₂;

X₁₆ is O, S, NH, NR, —O—CO, —NH—CO, —NR—CO, —O—SO₂, —NH—SO₂, or —NR—SO₂;

X₁₇ is O, S, NH, NR, —O—CO, —NH—CO, —NR—CO, —O—SO₂, —NH—SO₂, or —NR—SO₂;

X₁₈ is O, S, NH, NR, —O—CO, —NH—CO, —NR—CO, —O—SO₂, —NH—SO₂, or —NR—SO₂;

R is an aliphatic or aromatic substitution group;

R₆, R₇, and R₈ in formula (VIII) are the same or different;

In compounds represented by formula (VIII), R₆ represents an aliphatic chain with C₁-C₁₀ hydrocarbon; R₆ also represents an aliphatic chain with C₁-C₁₀ hydrocarbon which has one or more other atoms such as, but not limited to, O, S, or N in the backbone; R₆ also represents an aliphatic chain with C₁-C₁₀ hydrocarbon which has one or more aliphatic, aromatic, or both aliphatic and aromatic substitution groups on the backbone;

In compounds represented by formula (VIII), R₇ represents an aliphatic chain with C₁-C₁₀ hydrocarbon; R₇ also represents an aliphatic chain with C₁-C₁₀ hydrocarbon which has one or more other atoms such as, but not limited to, O, S, or N in the backbone; R₇ also represents an aliphatic chain with C₁-C₁₀ hydrocarbon which has one or more aliphatic, aromatic, or both aliphatic and aromatic substitution groups on the backbone; and

In compounds represented by formula (VIII), R₈ represents an aliphatic chain with C₁-C₁₀ hydrocarbon; R₈ also represents an aliphatic chain with C₁-C₁₀ hydrocarbon which has one or more other atoms such as, but not limited to, O, S, or N in the backbone; R₈ also represents an aliphatic chain with C₁-C₁₀ hydrocarbon which has one or more aliphatic, aromatic, or both aliphatic and aromatic substitution groups on the backbone.

In another aspect of the invention, compounds of the general formula (IX), or pharmaceutically acceptable salts thereof, are provided:

wherein:

Z₃ is a peptide containing 1-20 amide bonds and the boron atom attaches to a C atom, not an N atom nor —C═O;

R₁₀ is a substitution branch on backbone of Z₃;

R₁₀ forms ring F with boron in formula (IX);

the size of ring F counting all atoms on the ring is 4-10 atoms;

X₁₉ is directly attached to boron in ring F;

X₁₉ is O, S, NH, NR, —O—CO, —NH—CO, —NR—CO, —O—SO₂, —NH—SO₂, or —NR—SO₂; R is an aliphatic or aromatic substitution group;

In compounds represented by formula (IX), R₁₀ represents an aliphatic chain with C₁-C₁₀ hydrocarbon; R₁₀ also represents an aliphatic chain with C₁₀ hydrocarbon which has one or more other atoms such as, but not limited to, O, S, or N in the backbone; R₁₀ also represents an aliphatic chain with C₁-C₁₀ hydrocarbon which has one or more aliphatic, aromatic, or both aliphatic and aromatic substitution groups on the backbone;

In compounds represented by formula (IX), X₂O is directly attached to boron and is not in ring F;

X₂₀ is O, S, NH, NR, —O—CO, —NH—CO, —NR—CO, —O—SO₂, —NH—SO₂, or —NR—SO₂;

R is an aliphatic or aromatic substitution group;

In compounds represented by formula (IX), R₉ attaches to X₂₀; and

R₉ represents an aliphatic chain with C₁₋₁₀ hydrocarbon; R₉ also represents an aliphatic chain with C₁-C₁₀ hydrocarbon which has one or more other atoms such as, but not limited to, O, S, or N in the backbone; R₉ also represents an aliphatic chain with C₁-C₁₀ hydrocarbon which has one or more aliphatic, aromatic, or both aliphatic and aromatic substitution groups on the backbone.

In another aspect of the invention, a pharmaceutical composition comprises a compound of formula (I), (III), (IV), (V), (VI), (VII), (VIII), or (IX), or a pharmaceutically acceptable crystalline form thereof, suitable for the production of a drug in solid and/or liquid formulation.

Another aspect of the invention is directed to methods for the use of a pharmaceutical composition comprising one or more of the compounds described above to treat a patient who has or is at risk to have proteasome-mediated diseases, including cancers, or amyloidosis.

Non-toxic, pharmacologically acceptable salts useful herein comprise acid addition salts formed with inorganic or organic acids. Examples of suitable such salts include hydrohalides such as hydrochlorides, sulfates, hydrogen sulfates, phosphates, hydrogen phosphates, tartrates, succinates, maleates, benzoates, acetates, propionates, lactates, ascorbinates, and the like.

The compounds of formulae (I), (III), (IV), (V), (VI), (VII), (VIII), and (IX) according to the invention can be converted into their non-toxic, pharmacologically acceptable acid addition salts in conventional manner. Acids suitable for salt formation include, for example, hydrochloric acid, hydrobromic acid, hydriodic acid, hydrofluoric acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, propionic acid, butyric acid, caproic acid, valeric acid, oxalic acid, malonic acid, succinic acid, maleic acid, fumaric acid, lactic acid, tartaric acid, citric acid, malic acid, benzoic acid, p-hydroxybenzoic acid, p-aminobenzoic acid, phthalic acid, cinnamic acid, salicyclic acid, ascorbic acid, methanesulfonic acid, 8-chlorotheophyllin, and the like.

The compounds of formulae (I), (III), (IV), (V), (VI), (VII), (VIII), and (IX) and pharmaceutically acceptable salts thereof can be incorporated, optionally in combination with other active ingredients, into the usual pharmaceutical preparations such as tablets, coated tablets, capsules, powders, suppositories, or solutions. Such preparations may be produced with use of conventional pharmaceutical excipients, carriers, disintegrants, or lubricants or substances for obtaining delayed or sustained release. The single dose for adults is from about 0.1 to 80 mg (from about 0.0013 to 1.07 mg/kg), preferably, however, from about 1 to 30 mg (from about 0.013 to 0.40 mg/kg), 1 to 4 times daily.

Dependent upon the type and body weight of the patient to be treated, on the type and severity of the disease, on the type of preparation, and on the route of administration, which may be peroral, parenteral, or rectal, as well as on the period or interval over which the administration takes place, it may, however, be necessary to deviate from the above dosages. Thus, it may be sufficient in some cases to administer less than the above-mentioned amount of active ingredient or in some cases the amount may be exceeded.

The optimum dosage and route of administration of the active ingredients which are necessary in each case can easily be determined by one skilled in the art.

Another aspect of the invention is directed to a compound of the formula:

or a pharmaceutically acceptable salt, solvate, and/or hydrate, polymorph crystal or amorphous forms, thereof, wherein:

Z₃ is a peptide containing 1-20 amide bonds and boron atom attaches to a C atom, not an N atom nor —C═O;

Y₃ is C₁ to C₅, O, S, NH, or NR;

R represents an aliphatic or aromatic group with or without heteroatom or functional group, such as COOH, OH, or NH₂;

each Ra₁ and Ra₂ independently is H, aliphatic, or aromatic substitution group; each Ra₃ and Ra₄ independently is H, aliphatic, or aromatic substitution group;

q is 0, 1, or 2; and

r is 0, 1, or 2.

In another aspect of the invention, Z₃ is characterized by the bare bones structure or its derivatives of formula (XI-1):

In another aspect of the invention, Z₃ is characterized by the bare bones structure or its derivatives of formula (XI-2):

In another aspect of the invention, Z₃ is characterized by the bare bones structure or its derivatives of formula (XI-3):

In another aspect of the invention, the compound is one of:

Another aspect of the invention is directed to a compound of the formula:

or a pharmaceutically acceptable salt, solvate, and/or hydrate, polymorph crystal or amorphous form thereof, wherein:

Z₃ is a peptide containing 1-20 amide bonds and boron atom attaches to a C atom, not an N atom or —C═O;

each of Y₁, Y₂, and Y₃ independently is O, S, NH, or NR; Y₃ can also be C₁ to C₅;

R represents an aliphatic or aromatic group with or without heteroatom or functional group, such as COOH, OH, or NH₂;

each Rb₁ and Rb₂ independently is H, aliphatic, or aromatic substitution group; Rb₁ and Rb₂ can also be a double bond, such as carbonyl group; each Rb₃ and Rb₄ independently is H, aliphatic, or aromatic substitution group;

s is 0, 1, or 2; and

t is 0, 1, or 2.

Another aspect of the invention is directed to the compound characterized by the formula:

or a pharmaceutically acceptable salt, solvate, and/or hydrate, polymorph crystal or amorphous form thereof, wherein:

Z₃ is a peptide containing 1-20 amide bonds and boron atom attaches to a C atom, not an N atom nor —C═O;

each Rc₁ and Rc₂ independently is H, aliphatic, or aromatic substitution group; each Rc₃ and Rc₄ independently is H, aliphatic, or aromatic substitution group, —(CH2)_(p)—COOH and —(CH2)_(p)—COOR wherein R is an aliphatic or aromatic group, with or without heteroatom or functional group, such as COOH, OH, or NH₂; and

u is 0, 1, or 2.

In another aspect of the invention, the compound is characterized by the formula:

or a pharmaceutically acceptable salt, solvate, and/or hydrate, polymorph crystal or amorphous forms, thereof, wherein:

Z₃ is a peptide containing 1-20 amide bonds and boron atom attaches to a C atom, not an N atom nor —C═O; and

each Rd₁ and Rd₂ independently is H, aliphatic, aromatic substitution group, —(CH2)_(p)-COOH and —(CH2)_(p)-COOR wherein R is an aliphatic or aromatic group with or without heteroatom or functional group, such as COOH, OH, or NH₂.

In another aspect of the invention, the compound is characterized by the formula:

or a pharmaceutically acceptable salt, solvate, and/or hydrate, polymorph crystal or amorphous form thereof, wherein:

Z₃ is a peptide containing 1-20 amide bonds and boron atom attaches to a C atom, not an N atom nor —C═O;

each Re₁ and Re₂ independently is H, aliphatic, aromatic substitution group, —(CH2)_(p)-COOH and —(CH2)_(p)-COOR wherein R is an aliphatic or aromatic group with or without heteroatom or functional group, such as COOH, OH, or NH₂; and

each Re₃ and Re₄ independently is H, aliphatic, aromatic substitution group, —(CH2)_(p)-COOH and —(CH2)_(p)-COOR wherein R is an aliphatic or aromatic group.

In another aspect of the invention, the compound is characterized by the formula:

or a pharmaceutically acceptable salt, solvate, and/or hydrate, polymorph crystal or amorphous form thereof, wherein:

Z₃ is a peptide containing 1-20 amide bonds and boron atom attaches to a C atom, not an N atom nor —C═O;

each Rf₁ and Rf₂ independently is H, aliphatic, aromatic substitution group;

each Rf₃ and Rf₄ independently is H, aliphatic, aromatic substitution group, —(CH₂)_(p)—COOH and —(CH₂)_(p)—COOR wherein R is an aliphatic or aromatic group with or without heteroatom or functional group, such as COOH, OH, or NH₂; and

v is 0, 1, or 2.

In another aspect of the invention, the compound is characterized by the formula:

or a pharmaceutically acceptable salt, solvate, and/or hydrate, polymorph crystal or amorphous form thereof, wherein:

Z₃ is a peptide containing 1-20 amide bonds and boron atom attaches to a C atom, not an N atom nor —C═O;

R represents an aliphatic or aromatic group with or without heteroatom or functional group, such as COOH, OH, or NH₂;

each Rg₁ and Rg₂ independently is H, aliphatic, aromatic substitution group; each Rg₃ and Rg₄ independently is H, aliphatic, aromatic substitution group, —(CH2)_(p)-COOH and —(CH2)_(p)-COOR wherein R is an aliphatic or aromatic group with or without heteroatom or functional group, such as COOH, OH, NH₂; and

w is 0, 1, or 2.

In another aspect of the invention, the compound is one of the following:

In another aspect of the invention, a medically useful composition comprises one or more of the compounds described herein in combination with pharmaceutically acceptable excipients, formulates as drugs in solid or liquid forms.

In another aspect of the medically useful compositions of the invention, the one or more compounds are present in an amount effective to treat cancer, a cancerous condition, such as multiple myeloma, or amyloidosis in a human or mammal.

Another aspect of the invention is directed a process for the preparation of compounds of the formula:

or a pharmaceutically acceptable salt, solvate, and/or hydrate, polymorph crystal or amorphous form thereof, wherein:

Z₃ is a peptide containing 1-20 amide bonds and boron atom attaches to a C atom, not an N atom nor —C═O;

Y₃ is C₁ to C₅, O, S, NH, or NR; R represents an aliphatic or aromatic group with or without heteroatom or functional group, such as COOH, OH, or NH₂;

each Ra₁ and Ra₂ independently is H, aliphatic, aromatic substitution group;

each Ra₃ and Ra₄ independently is H, aliphatic, aromatic substitution group;

q is 0, 1, or 2; and

r is 0, 1, or 2.

In another aspect of the invention, a compound of formula (XI-1) is reacted with N-methyliminodiacetic acid to form a compound of formula (X-2):

wherein, HL01-0 is XI-1 and HL01-011 is X-2.

In another aspect of the invention, a compound of formula (XI-3) is reacted with N-methyliminodiacetic acid to form a compound of formula (X-2):

wherein, HL01-00 is XI-3 and HL01-015 is X-2.

In another aspect of the invention, a compound of formula (XI-2) is reacted with N-methyliminodiacetic acid to form a compound of formula (X-2):

wherein, HL01-000 is XI-2 and HL01-016 is X-2.

In another aspect of the invention, a compound of formula (XI-1) is reacted with EDTA to form a compound of formula (X-2):

wherein, HL01-0 is XI-1 and HL01-08 is X-2.

In another aspect of the invention, a compound of formula (XI-1) is reacted with EDTA to form a compound of formula (X-2):

wherein, HL01-0 is XI-1 and HL01-08-1 is X-2.

In another aspect of the invention, a compound of formula (XI-1) is reacted with N-ethyl-iminodiacetic acid to form a compound of formula (X-2):

wherein, HL01-0 is XI-1 and HL01-34 is X-2.

In another aspect of the invention, a compound of formula (XI-1) is reacted with N-methyldiethanolamine to form a compound of formula (XII):

wherein, HL01-0 is XI-1 and HL01-33 is XII.

In another aspect of the invention, a compound of formula (XI-3) is coupled or reacted with an ester of amino substituted L-tartaric acid derivative to form a compound of formula (XI):

wherein, HL01-00 is XI-3 and HL-245 is XI.

In another aspect of the invention, a compound of formula (XI-1) is reacted with N-methyliminodiacetic acid to form a compound of formula (XII):

wherein, HL01-0 is XI-1 and HL-448 is XII.

In another aspect of the invention, a compound of formula (XI-1) is coupled or reacted with N-ethyldiethanolamine to form a compound of formula (XII):

wherein, HL01-0 is XI-1 and HL-505 is XII.

In another aspect of the invention, a composition for treating cancer, a cancerous condition, or amyloidosis in a human or mammal, comprises as active ingredient a pharmaceutically effective amount of a compound described herein, including, but not limited to, a compound of formulae (I), (III), (IV), (V), (VI), (VII), (VIII), and (IX) or a pharmaceutically acceptable acid addition salt thereof, in combination with pharmaceutically acceptable carriers, diluents, or excipients.

In another aspect of the invention, the composition comprises active ingredient in an amount effective to treat multiple myeloma or amyloidosis.

In another aspect of the invention, in a method of treating cancer, a cancerous condition, or amyloidosis in a human or mammal host in need of such treatment, the method comprises perorally, parentally, or rectally administering to said host an effective cancer, cancerous condition, or amyloidosis treatment amount of a compound of formula (I), (III), (IV), (V), (VI), (VII), (VIII), or (IX) or a pharmaceutically acceptable acid addition salt thereof.

BRIEF DESCRIPTION OF THE DRAWING

The FIGURE is a graph that represents the results of testing to demonstrate the cytotoxic effects of certain compounds, including compounds prepared according to the invention.

DETAILED DESCRIPTION OF THE INVENTION

The invention can perhaps be appreciated better from the description below, where compounds of the invention have been prepared and then some testing is described.

EXAMPLES

Boronic acid can readily form oligomeric anhydrides by dehydration of the boronic acid moiety. Hence, the monomeric structure form drawn below, such as HL01-0 drawn in the Example 1, is expressly intended to represent the free boronic acid, oligomeric anhydrides, including, but not limited to, dimers, trimers, and tetramers, and mixtures thereof.

Abbreviations: Bortezomib (HL01-0), Tetrahydrofuran (THF), Ethyl Acetate (EtOAc or EA), N,N-Dimethylsulfoxide (DMSO), Ethylenediaminetetraacetic Acid (EDTA), Hydrogen Chloride (HCl), room temperature (RT), Nuclear Magentci Resonance (NMR), Reverse Phase High Performance Liquid Chromatography (RP-HPLC), Liquid Chromatography-Mass Spectroscopy (LC-MS)

General Characterization Methods: ¹H NMR, ¹³C NMR, HPLC, LCMS.

The product HL01-01 of Example 1, characterized by formula HL01-01-1, HL-01-01-2, HL-01-01-3, HL-01-01-4, HL-1-01-5, or a mixture thereof.

The product HL01-02 of Example 2, characterized by formula HL01-02-1, HL-01-02-2, HL-01-02-3, HL-01-02-4, or a mixture thereof.

The product HL01-17 of Example 15, characterized by formula HL01-17-1, HL-01-17-2, HL-01-17-3, HL-01-17-4, HL-1-17-5, or a mixture thereof.

The product HL01-18 of Example 16, characterized by formula HL01-18-1, HL-01-18-2, HL-01-18-3, HL-01-18-4, HL-1-18-5, or a mixture thereof.

The product HL01-23 of Example 23, characterized by formula HL01-23-1, HL-01-23-2, HL-01-23-3, HL-01-23-4, or a mixture thereof.

The product HL01-28 of Example 28, characterized by formula HL01-28-1, HL-01-28-2, HL-01-28-3, HL-01-28-4, or a mixture thereof.

Example 1

Bortezomib (HL01-0, 1.0 g) was dissolved in EA (80 mL) at 85° C., and citric acid (525 mg, 2.73 mmol) was added under inert gas. The reaction mixture was stirred at 85° C. for another 3.5 hrs, then cooled to room temperature (RT), and n-Hexane (24 mL) was added. The white precipitate was filtered and dried to get the white solid HL-01-01. ¹H NMR (d₆-DMSO, 400 MHz) δ 12.08 (br, 1H), 10.62 (br, 1H), 9.19 (br, 1H), 9.18 (s, 1H), 8.89 (s, 1H), 8.77 (s, 1H), 7.28-7.19 (m, 5H), 5.06 (m, 1H), 3.25 (d, 2H, J=6.8 Hz), 2.85 (m, 1H), 2.72 (m, 2H), 2.57 (m, 2H), 1.45 (m, 1H), 1.10 (m, 1H), 0.97 (m, 1H), 0.78 (d, 6H, J=4.4 Hz). ¹³C NMR (d₆-DMSO, 400 MHz) δ 177.82, 170.73, 170.62, 163.28, 147.84, 143.98, 143.71, 143.39, 129.28, 128.31, 126.79, 76.24, 50.31, 36.25, 24.55, 23.51, 21.38.

Example 2

HL01-0 (100 mg) was dissolved in DMSO (2 mL), and L-malic acid (35 mg, 0.26 mmol) was added under inert gas. The reaction mixture was stirred at 95° C. for 6 hrs, then cooled to RT. The solvent was removed under reduced pressure, then EA/n-Hexane was added to the residue at −20° C. The white precipitate was filtered and dried to get the white solid, HL-01-02. ¹H NMR (d₆-DMSO, 400 MHz) δ 12.30 (br, 1H), 10.72 (s, 1H), 9.33 (d, 1H, J=7.6 Hz), 9.13 (d, 1H, J=1.6 Hz), 8.89 (d, 1H, J=1.6 Hz), 8.78 (m, 1H), 7.28-7.21 (m, 5H), 5.07 (dd, 1H, J=15.2, 7.6 Hz), 4.37 (dd, 1H, J=7.2, 4.0 Hz), 3.46-3.42 (m, 1H), 3.29-3.20 (m, 2H), 2.63-2.28 (m, 2H), 1.46 (m, 1H), 1.17 (m, 2H), 0.81 (d, 6H, J=6.4 Hz). MS (m/z): [M+Na] calculated for C₂₃H₂₇BN₄NaO₇, 505.28; found, 505.19.

Example 3

HL01-0 (200 mg) was dissolved in EA (8 mL) at 85° C., and diethanolamine (54.7 mg, 0.52 mmol) was added under inert gas. The reaction mixture was stirred at 85° C. for 6 hrs. then was cooled to RT. The white precipitate was collected and dried to get the white solid. (150 mg, 63. ¹H NMR (d₆-DMSO, 400 MHz) δ 9.09 (s, 1H), 8.87 (d, 1H, J=2.4 Hz), 8.81 (d, 1H, J=8.8 Hz), 8.75 (s, 1H), 7.28-7.20 (m, 5H), 7.16-7.14 (m, 1H), 6.55 (br, 1H), 4.76 (td, 1H, J=9.2, 4.8 Hz), 3.69-3.61 (m, 2H), 3.28-3.23 (m, 1H), 3.48-3.41 (m, 1H), 3.16-3.04 (m, 3H), 2.85-2.77 (m, 1H), 2.74-2.67 (m, 2H), 1.63-1.53 (m, 1H), 1.37-1.30 (m, 1H), 1.22-1.16 (m, 1H), 0.80 (dd, 6H, J=12.8, 6.8 Hz).

Example 4

HL01-0 (384 mg) was dissolved in DMSO (3 mL) and EA (3 mL), and Iminodiacetic Acid (133 mg, 1 mmol) was added under inert gas. The reaction mixture was stirred at 85° C. for 6 hrs, then was cooled to RT. The white precipitate was collected under reduced pressure, washed by EtOH, and dried to get the white solid. ¹H NMR (d₆-DMSO, 400 MHz) δ 9.09 (d, 1H, J=1.2 Hz), 8.87 (d, 1H, J=2.4 Hz), 8.73-8.72 (m, 1H), 8.70 (d, 1H, J=8.8 Hz), 8.16 (br, 1H), 7.76 (d, 1H, J=8 Hz), 7.26-7.13 (m, 5H), 4.72 (td, 1H, J=8.8, 5.6 Hz), 4.06 (dd, 1H, J=17.2, 8.4 Hz), 3.92 (dd, 1H, J=17.6, 8.4 Hz), 3.76 (dd, 1H, J=9.2, 3.2 Hz), 3.72 (dd, 1H, J=9.2, 3.2 Hz), 3.14-3.01 (m, 3H), 1.59-1.45 (m, 2H), 1.08-1.01 (m, 1H), 0.82 (dd, 6H, J=22.4, 6.8 Hz). MS (m/z): [M+H] calculated for C₂₃H₂₉BN₅O₆, 482.32; found, 482.15.

Example 5

HL01-0 (19.2 mg) was dissolved in DMSO (1.5 mL), and EDTA (7.3 mg, 0.05 mmol) was added under inert gas. The reaction mixture was stirred at 100° C. for 3 hrs, then was cooled to RT. The white precipitate was collected under reduced pressure, and dried get the white solid. MS (m/z): [M+H] calculated for C₂₉H₃₈BN₆O₁₀, 641.46; found, 641.30.

Example 6

HL01-0 (50 mg) was dissolved in DMSO (2 mL), and EDTA (19 mg, 0.065 mmol) was added under inert gas. The reaction mixture was stirred at 105° C. for 4 hrs., then was cooled to RT. The white precipitate was collected under reduced pressure, purified by semi-prep RP-HPLC, and dried get the white solid. MS (m/z): [M+H] calculated for C₄₈H₅₉B₂N₁₀O₁₂, 989.67; found, 989.2.

Example 7

HL01-0 (200 mg) was dissolved in DMSO/EA (6 mL/6 mL), and N-methyliminodiacetic acid 133 mg, 0.52 mmol) as added under inert gas. The reaction mixture was stirred at 85° C. for 5 hrs, and then was cooled to RT. The white precipitate was collected under reduced pressure, and dried to get the white solid. ¹H NMR (d₆-DMSO, 400 MHz) δ 9.07 (d, 1H, J=1.2 Hz), 8.92 (d, 1H, J=4.4 Hz), 8.87 (d, 1H, J=2.4 Hz), 8.74-8.73 (m, 1H), 7.30-7.23 (m, 5H), 7.20-7.15 (m, 1H), 4.70-4.64 (m, 1H), 4.22 (d, 1H, J=17.2 Hz), 4.07 (d, 1H, J=16.8 Hz), 3.98 (d, 1H, J=16.8 Hz), 3.57-3.51 (m, 2H), 3.09 (s, 1H), 3.07 (d, 1H, J=2.0 Hz), 2.82 (s, 3H), 1.59-1.53 (m, 1H), 1.43-1.36 (m, 1H), 1.22-1.16 (m, 1H), 0.84 (dd, 6H, J=11.2, 6.4 Hz). MS (m/z): [M+H] calculated for C₂₄H₃₁BN₅O₆, 496.34; found, 496.20.

Example 8

HL01-0 (150 mg) was dissolved in DMSO (5 mL), and N-isopropyl iminodiacetic acid (HL01-12-0, 69 mg, 0.39 mmol) as added under inert gas. The reaction mixture was stirred at 85° C. for 5 hrs, and then was cooled to RT. The solvent was removed under reduced pressure to get colorless oil. ¹H NMR (d₆-DMSO, 400 MHz) δ 9.09 (d, 1H, J=1.6 Hz), 8.91 (d, 1H, J=8.4 Hz), 8.86 (d, 1H, J=2.4 Hz), 7.44 (d, 1H, J=9.6 Hz), 7.30-7.16 (m, 5H), 4.68-4.62 (m, 1H), 4.28 (d, 1H, J=18.0 Hz), 3.89 (dd, 2H, J=18.4, 5.2 Hz), 3.71-3.61 (m, 3H), 3.09 (s, 1H), 3.07 (d, 1H, J=2.8 Hz), 1.61-1.55 (m, 1H), 1.49-1.42 (m, 1H), 1.16 (dd, 6H, J=6.0, 2.0 Hz), 0.99 (d, 1H, J=6.8 Hz), 0.84 (dd, 6H, J=29.2, 6.8 Hz). MS (m/z): [M+H] calculated for C₂₆H₃₅BN₅O₆, 524.4; found, 524.30.

Example 9

HL01-0 (200 mg) was dissolved in DMSO (3 mL), and N-benzyl iminodiacetic acid (HL01-13-0, 122 mg, 0.547 mmol) as added under inert gas. The reaction mixture was stirred at 85° C. for 2 hrs, then was cooled to RT. The solvent was removed under reduced pressure to get colorless oil. ¹H NMR (d₆-DMSO, 400 MHz) δ 9.12 (d, 1H, J=1.6 Hz), 9.06 (d, 1H, J=8.0 Hz), 8.87 (d, 1H, J=2.0 Hz), 8.75 (dd, 1H, J=2.4, 1.6 Hz), 7.63-7.61 (m, 1H), 7.52-7.50 (m, 2H), 7.34-7.17 (m, 7H), 4.66-4.60 (m, 1H), 4.465 (d, 1H, J=13.2 Hz), 4.26 (d, 1H, J=13.2 Hz), 4.18 (d, 1H, J=17.2 Hz), 3.85-3.77 (m, 2H), 3.68-3.63 (m, 1H), 3.15-3.00 (m, 3H), 1.66-1.60 (m, 1H), 1.56-1.45 (m, 1H), 1.35-1.26 (m, 1H), 0.89 (dd, 6H, J=11.2, 6.8 Hz). MS (m/z): [M+H] calculated for C₃₀H₃₅BN₅O₆, 572.44; found, 572.30.

Example 10

HL01-0 (200 mg) was dissolved in EA (5 mL), and Pinacol (61.5 mg) was added under inert gas. The reaction mixture was stirred at 85° C. for 5 hrs, and then was cooled to RT, and the solvent was removed under reduced pressure to get the oil. ¹H NMR (d₆-DMSO, 400 MHz) δ 9.18 (d, 1H, J=1.2 Hz), 8.99-8.98 (m, 1H), 8.94 (d, 1H, J=2.8 Hz), 8.84 (d, 1H, 8.4 Hz), 8.91-8.80 (m, 1H), 7.33-7.23 (m, 5H), 4.96-4.91 (m, 1H), 3.19-3.17 (m, 2H), 2.70-2.66 (m, 1H), 1.65-1.56 (m, 1H), 1.37-1.31 (m, 1H), 1.27-1.23 (m, 1H), 1.18 (d, 12H, J=4.8 Hz), 0.88 (t, 6H, J=6.4 Hz). MS (m/z): [M+H] calculated for C₂₅H₃₆BN₄O₄, 467.28; found: 467.30.

Example 11

Chloroacetic acid (6 g, 0.0625 mol) was dissolved in water (20 mL) at 0° C., then neutralized with 5 N NaOH solution. Isopropylamine (1.85 g, 0.031 mol) was added to the solution and stirred at 50° C. overnight. BaCl₂ 2H₂O (7.6 g, 0.031 mol) was dissolved in hot water (15 mL) and was added to the reaction mixture. The precipitate was filtered and dried at 60° C. for 2 hours. The solid was dissolved in the boiling water, and 5N H₂SO₄ was added. After removal of the precipitate, the filtrate was concentrated to give brown solid, HL01-12-0 (300 mg, 5.5%) H NMR (d6-DMSO, 400 MHz) δ 3.27 (s, 4H), 3.12 (s, 1H), 1.02 (s, 6H).

Example 12

Chloroacetic acid (18.9 g, 0.2 mol) was dissolved in water (30 mL) at 0° C., then neutralized with 5 N NaOH solution. Benzylamine (10.7 g, 0.1 mol) was added to the solution and stirred at 60° C. overnight. BaCl₂ 2H₂O (25.6 g, 0.105 mol) was dissolved in hot water (30 mL) and was added to the reaction mixture. The precipitate was filtered and dried at 80° C. for 4 hours. The solid was dissolved in the boiling water, and 5N H₂SO₄ was added. After removal of the precipitate, the filtrate was concentrated to give white solid, HL01-13-0 (8.0 g, 36%). ¹H NMR (d6-DMSO, 400 MHz) δ 7.33-7.24 (m, 5H), 3.82 (s, 2H), 3.38 (s, 4H).

Example 13

HL01-00 (30 mg, 0.083) was dissolved in DMSO (2 mL), and N-Methyl iminodiacetic acid (12.2 mg, 0.083 mmol) was added under inert gas. The reaction mixture was stirred at 85° C. for 2 hrs, then was cooled to RT. The solvent was removed under reduced pressure and the residue purified by Prep-HPLC to get the white solid, HL01-15 (15 mg, 38.5%)¹H NMR (d6-DMSO, 400 MHz) δ 8.84 (s, 1H), 7.54-7.52 (m, 3H), 7.33 (d, 1H, J=8.8 Hz), 4.26-4.13 (m, 3H), 4.02-3.80 (m, 4H), 2.87 (s, 3H), 1.53-1.52 (m, 1H), 1.41-1.35 (m, 1H), 1.20-1.16 (m, 1H), 0.85 (m, 6H). MS (m/z): [M+H] calculated for C₁₉H₂₅BCl₂N₃O₆, 472.12; found, 472.00.

Example 14

HL01-000 (30 mg) was dissolved in DMSO (2 mL), and N-Methyl iminodiacetic acid (10.7 mg, 0.073 mmol) was added under inert gas. The reaction mixture was stirred at 85° C. for 2 hrs, then was cooled to RT. The solvent was removed under reduced pressure and the residue was purified by Prep-HPLC to get the white solid, HL01-17 (10 mg, 36.3%). ¹H NMR (d₆-DMSO, 400 MHz) δ 8.80 (d, 1H, J=8.4 Hz), 8.21-8.17 (m, 3H), 8.11 (t, 1H, J=8.0 Hz), 8.00 (d, 1H, J=6.8 Hz), 7.59-7.25 (m, 4H), 5.21-5.20 (m, 1H), 4.51 (dd, 1H, J=8.4, 3.6 Hz), 4.28 (d, 1H, J=17.6 Hz), 4.12 (d, 1H, J=16.8 Hz), 4.08 (br, 1H), 3.97 (d, 1H, J=17.2 Hz), 3.92 (d, 1H, J=16.4 Hz), 2.94 (s, 3H), 1.55-1.48 (m, 1H), 1.45-1.37 (m, 1H), 1.22-1.15 (m, 1H), 1.09 (d, 3H, J=6.0 Hz), 0.82 (dd, 6H, J=16.8, 6.8 Hz). MS (m/z): [M+H] calculated for C₂₆H₃₄BN₄O₇, 525.25; found, 525.30.

Example 15

To a solution of HL01-00 (30 mg) in EA (2 mL) was added citric acid (16 mg, 0.083 mmol) at sealed tube. The reaction mixture was stirred at 85° C. for 1.5 hrs. The reaction mixture was cooled to RT, and the solid was filtered to get the product white solid, HL01-17. (˜15 mg, 35.7%)¹H NMR (d₆-DMSO, 400 MHz) δ 12.18 (br, 1H), 10.72 (s, 1H), 9.13 (s, 1H), 7.66 (s, 1H), 7.57 (d, 2H, J=1.2 Hz), 4.27 (br, 2H), 2.92-2.88 (m, 1H), 2.78-2.74 (m, 1H), 2.67-2.63 (m, 1H), 2.53 (s, 1H), 1.68-1.67 (m, 1H), 1.29-1.77 (m, 3H), 0.87 (d, 6H, J=6.4 Hz).

Example 16

HL01-000 (30 mg) was dissolved in DMSO (2 mL) at RT, and then citrate (14 mg, 0.073 mmol) was added. The reaction mixture was stirred at 85° C. under inert gas for another 4 hrs, then cooled to RT, The solvent was removed to get solid (15 mg). ¹H NMR (d₆-DMSO, 400 MHz) δ 12.14 (s, 1H), 10.78 (s, 1H), 8.81-8.79 (d, 1H, J=8.4 Hz), 8.24-8.19 (m, 3H), 8.15-8.11 (t, 1H), 8.04-8.03 (d, 1H, J=7.2 Hz), 7.58-7.49 (m, 3H), 5.7 (s, 1H), 4.72-4.69 (dd, 1H), 4.27 (s, 1H), 2.90-2.67 (m, 4H), 1.62 (s, 1H), 1.30-1.14 (d, 5H), 0.83-0.82 (d, 6H, J=6.4 Hz)

Example 17

HL01-000 (30 mg) was dissolved in DMSO (2 mL) at RT, and then iminodiacetic acid (9.71 mg, 0.073 mmol) was added. The reaction mixture was stirred at 85° C. under inert gas for another 5 hrs, then cooled to RT. The solvent was removed to get white crystalline solid, HL01-19 (15 mg). ¹H NMR (d₆-DMSO, 400 MHz) δ 8.78-8.76 (d, 1H, J=8.0 Hz), 8.21-8.16 (m, 3H), 8.12-8.08 (t, 2H), 8.02-8.00 (d, 1H), 7.74-7.73 (d, 1H, J=7.6 Hz), 7.58-7.49 (m, 3H), 5.16 (s, 1H), 4.41-4.38 (q, 1H), 4.15-4.07 (m, 3H), 3.79-3.72 (m, 2H), 3.19-3.13 (m, 1H), 1.65-1.62 (m, 1H), 1.56-1.48 (m, 1H), 1.11-1.04 (m, 3H), 0.86-0.85 (d, 3H=6.8 Hz), 0.80-0.78 (d, 3H, J=6.4 Hz). MS (m/z): [M+H] calculated for C₂₅H₃₂BN₄O₇, 511.35; found, 511.0.

Example 18

HL01-000 (30 mg) was dissolved in DMSO (2 mL) at RT, and Pinacol (8.61 mg, 0.073 mmol) was added. The reaction mixture was stirred at 85° C. under inert gas for another 5 hrs, then cooled to RT. The solvent was removed to get solid, HL01-20 (10 mg). ¹H NMR (d₆-DMSO, 400 MHz) δ 9.11 (s, 1H), 8.78-8.76 (d, 1H, J=8.4 Hz), 8.23-8.19 (m, 3H), 8.13-8.10 (t, 1H), 8.03-8.01 (d, 1H, J=7.2 Hz), 7.57-7.50 (m, 4H), 5.32-5.31 (d, 1H, J=4.8 Hz), 4.55-4.51 (dd, 1H), 4.15-4.11 (dd, 1H), 1.68-1.64 (m, 1H), 1.29-1.20 (m, 2H), 1.14-1.09 (m, 12H), 0.85-0.83 (dd, 6H)

Example 19

HL01-000 (30 mg) was dissolved in DMSO (2 mL) at RT, and N-isopropyl iminodiacetic (8.61 mg, 0.073 mmol) was added. The reaction mixture was stirred at 85° C. under inert gas for another 5 hrs, and then cooled to RT. The solvent was removed to get pale yellow sticky solid, HL01-21. ¹H NMR (d₆-DMSO, 400 MHz) δ 8.76-8.74 (d, 1H, J=8.4 Hz), 8.18-8.16 (m, 3H), 8.12-8.08 (t, 1H), 8.02-8.00 (d, 1H), 7.59-7.51 (m, 4H), 5.17 (s, 1H), 4.56-4.53 (dd, 1H), 4.33-4.28 (d, 1H), 4.08 (s, 1H), 3.99-3.89 (d, 3H), 3.83-3.80 (t, 1H), 3.71-3.67 (t, 1H), 1.59-1.37 (m, 3H), 1.23-1.10 (dd, 6H), 0.86-0.79 (m, 6H) MS (m/z): [M+H] calculated for C₂₈H₃₈BN₄O₇, 553.43; found, 553.3.

Example 20

HL01-000 (30 mg) was dissolved in DMSO (2 mL) at RT, and EDTA (10.65 mg, 0.037 mmol) was added, the reaction mixture was stirred at 98° C. under inert gas for another 6 hrs, then cooled to RT. The solvent was removed to get solid which was purified by RP-HPLC to give HL01-220-1 and dimer HL01-22-2. HL01-22-1 MS (m/z): [M+H] calculated for C₃₁H₄₁BN₅O₁₄, 670.28; found, 670.2. HL01-22-2 MS (m/z): [M+H] calculated for C₅₂H₆₅B₂N₈O₁₄, 1047.47; found, 1047.1.

Example 21

HL01-000 (30 mg) was dissolved in DMSO (2 mL) at RT, and L-malic acid (9.79 mg, 0.073 mmol) was added, the reaction mixture was stirred at 98° C. under inert gas for another 6 hrs, then cooled to RT. The solvent was removed to get solid. ¹H NMR (d₆-DMSO, 400 MHz) δ 12.30 (s, 1H), 10.87 (s, 1H), 8.83-8.81 (d, 1H, J=8 Hz), 8.24-8.02 (m, 5H), 7.59-7.52 (m, 3H), 5.77-5.76 (d, 1H, J=5.2 Hz), 4.76-4.73 (m, 1H), 4.41-4.39 (m, 1H), 4.32-4.29 (m, 1H), 2.68-2.57 (m, 2H), 1.63-1.56 (m, 1H), 1.31-1.26 (t, 2H), 1.19-1.18 (d, 3H, J=6.4 Hz), 0.84-0.83 (d, 6H, J=6.4 Hz)

Example 22

HL01-00 (30 mg) was dissolved in DMSO (2 mL) at RT, and Iminodiacetic Acid (11.03 mg, 0.083 mmol) was added. The reaction mixture was stirred at 85° C. under inert gas for another 5 hrs, then cooled to RT. The solvent was removed to get solid. ¹H NMR (d6-DMSO, 400 MHz) δ 8.75-8.72 (t, 1H), 8.19 (s, 1H), 7.69-7.68 (m, 1H), 7.52-7.51 (d, 2H, J=1.2 Hz), 4.15-4.0 (m, 2H), 3.88-3.72 (m, 4H), 3.14-3.08 (m, 1H), 1.65-1.62 (m, 1H), 1.54-1.46 (m, 1H), 1.12-1.06 (m, 1H), 0.88-0.81 (dd, 6H, J=6.8, 21.6 Hz). MS (m/z): [M+H] calculated for C18H22BCl2N3O6, 458.09; found, 458.4.

Example 23

HL01-00 (30 mg) was dissolved in EA (2 mL) at RT, and pinacol (9.79 mg, 0.083 mmol) was added. The reaction mixture was stirred at 98° C. under inert gas for another 6 hrs, then cooled to RT. The solvent was removed to get solid. ¹H NMR (d₆-DMSO, 400 MHz) δ 9.07 (s, 1H), 8.88-8.85 (t, 1H), 7.70 (s, 1H), 7.53 (s, 2H), 4.04-4.02 (d, 2H, J=6 Hz), 2.66-2.57 (m, 1H), 1.71-1.67 (m, 2H), 1.52-1.47 (m, 1H), 1.08 (s, 12H), 0.87-0.84 (t, 6H)

Example 24

HL01-00 (30 mg) was dissolved in DMSO (1 mL) at RT, and N-isopropyl iminodiacetic acid (14.53 mg, 0.083 mmol) was added. The reaction mixture was stirred at 98° C. under inert gas for another 6 hrs, then cooled to RT. The solvent was removed to get solid. ¹H NMR (d₆-DMSO, 400 MHz) δ 8.78 (s, 1H), 7.68 (s, 1H), 7.49-7.47 (d, 3H, J=8 Hz), 4.32-4.28 (d, 1H, J=16.8 Hz), 4.05-3.88 (m, 4H), 3.74-3.67 (m, 3H), 1.54 (s, 1H), 1.44-1.38 (t, 2H), 1.23-1.06 (m, 7H), 0.86-0.82 (d, 6H, J=15.2 Hz). MS (m/z): [M+H] calculated for C₂₁H₂₉BCl₂N₃O₆, 501.18; found, 502.1.

Example 25

HL01-00 (30 mg) was dissolved in DMSO (1 mL) at RT, and EDTA (24.23 mg, 0.083 mmol) was added. The reaction mixture was stirred at 98° C. under inert gas for another 6 hrs, then cooled to RT. The solvent was removed to get solid which was purified by RP-HPLC to obtain HL01-27-1 and dimer HL01-27-2. HL01-27-1 MS (m/z): [M+H] calculated for C₂₄H₃₂BCl₂N₄O₁₀, 618.24; found, 618.4; HL01-27-2 MS (m/z): [M+H] calculated for C₃₈H₄₇B₂Cl₄N₆O₂, 943.24; found: 943.4.

Example 26

HL01-00 (30 mg) was dissolved in DMSO (1 mL) at RT, and L-malic acid (11.12 mg, 0.083 mmol) was added. The reaction mixture was stirred at 98° C. under inert gas for another 6 hrs, then cooled to RT. The solvent was removed to get solid. ¹H NMR (d₄-CD₃OD, 400 MHz) δ 7.59-7.56 (t, 2H), 7.46 (dd, 1H, J=2 Hz, 8.4 Hz), 4.591-4.565 (q, 1H), 4.37 (s, 2H), 2.87-2.78 (m, 2H), 2.61-2.58 (m, 1H), 1.74-1.64 (m, 1H), 1.47-1.43 (t, 2H), 0.96-0.94 (dd, 6H, J=2.8 Hz, 6.8 Hz)

Example 27

HL01-00 (30 mg) was dissolved in DMSO (1 mL) at RT, and Nitrilotriacetic acid (15.85 mg, 0.083 mmol) was added. The reaction mixture was stirred at 85° C. under inert gas for another 5 hrs, then cooled to RT. The solvent was removed to get solid. ¹H NMR (d₆-DMSO, 400 MHz) δ 8.81-8.78 (t, 1H), 7.69-7.68 (t, 1H), 7.50-7.38 (m, 3H), 4.43-4.38 (d, 1H, J=20 Hz), 4.30-4.25 (d, 1H, J=16.8 Hz), 4.21-4.00 (m, 4H), 3.91-3.86 (dd, 1H, J=5.2 Hz, 15.6 Hz), 3.68-3.63 (dd, 1H, J=6.4 Hz, 16 Hz), 3.59-3.53 (m, 1H), 1.56-1.53 (m, 1H), 1.39-1.36 (m, 1H), 1.21-1.17 (m, 1H), 0.85 (dd, 6H, J=6.4 Hz, 14 Hz). MS (m/z): [M+H] calculated for C₂₀H₂₅BCl₂N₃O₈, 517.14; found, 517.3.

Example 28

HL01-000 (30 mg) was dissolved in DMSO (1 mL) at RT, and Nitrilotriacetic acid (13.94 mg, 0.073 mmol) was added. The reaction mixture was stirred at 85° C. under inert gas for another 5 hrs, then cooled to RT. The solvent was removed to get solid. ¹H NMR (d₆-DMSO, 400 MHz) δ 8.83-8.78 (t, 1H), 8.22-8.18 (t, 2H), 8.12-8.08 (t, 1H), 8.03-7.98 (t, 1H), 7.59-7.48 (m, 5H), 4.53-4.50 (m, 1H), 4.46-4.42 (d, 1H, J=17.6 Hz), 4.35-4.02 (m, 4H), 3.61-3.55 (m, 1H), 3.50 (s, 2H), 1.55-1.46 (m, 1H), 1.45-1.38 (m, 2H), 1.10-1.08 (d, 3H, J=6.4 Hz), 0.85-0.79 (m, 6H). MS (m/z): [M+H] calculated for C₂₇H₃₄BN₄O₉, 569.38; found, 569.5.

Example 29

HL01-0 (30 mg) was dissolved in DMSO (1 mL) at RT, and Nitrilotriacetic acid (14.89 mg, 0.078 mmol) was added. The reaction mixture was stirred at 85° C. under inert gas for another 6 hrs, then cooled to RT. The solvent was removed to get solid. ¹H NMR (d₆-DMSO, 400 MHz) δ 9.07-9.06 (d, 1H, J=1.2 Hz), 8.92-8.83 (m, 2H), 8.74-8.70 (m, 1H), 7.40-7.38 (d, 1H, J=10 Hz), 7.29-7.12 (m, 5H), 4.71-4.65 (m, 1H), 4.40-4.04 (m, 4H), 3.55-3.55 (m, 3H), 3.09-3.06 (m, 2H), 1.60-1.51 (m, 1H), 1.45-1.38 (m, 1H), 1.23-1.17 (m, 1H), 0.84 (dd, 6H, J=6.4 Hz, 18.4 Hz). MS (m/z): [M+H] calculated for C₂₅H₃₁BN₅O_(, 540.35); found, 540.3.

Example 30

HL01-0 (30 mg) was dissolved in DMSO (1 mL) at RT, and L(+)-tartaric acid (11.70 mg, 0.078 mmol) was added, The reaction mixture was stirred at 85° C. under inert gas for another 5 hrs, then cooled to RT, The solvent was removed to get solid. ¹H NMR (d₆-DMSO, 400 MHz) δ12.75 (bs, 1H), 10.77 (s, 1H), 9.38-9.35 (t, 1H), 9.12 (s, 1H), 8.90-8.89 (d, 1H, J=2.4 Hz), 8.78-8.77 (t, 1H), 7.29-7.18 (m, 5H), 5.12-5.07 (q, 1H), 4.49-4.21 (q, 2H), 3.32-3.21 (m, 2H), 2.68-2.57 (m, 1H), 1.55-1.37 (m, 1H), 1.23-1.06 (m, 2H), 0.86-0.79 (q, 6H).

Example 31

HL01-0 (60 mg) was dissolved in Ethyl acetate (1 mL) at RT, and N-methyldiethanolamine (18.56 mg, 0.156 mmol) was added. The reaction mixture was stirred at RT under inert gas for another 5 hrs, then solvent was removed to get solid. ¹H NMR (d₆-DMSO, 400 MHz) δ 9.24-9.22 (d, 1H, J=8.4 Hz), 9.09-9.08 (d, 1H, J=1.2 Hz), 8.89-8.88 (d, 1H, J=2.4 Hz), 8.79-8.78 (m, 1H), 7.30-7.12 (m, 5H), 6.74-6.72 (d, 1H, J=10 Hz), 4.67-4.61 (m, 1H), 3.61-3.55 (m, 3H), 3.21-3.0 (m, 6H), 2.90-2.86 (m, 1H), 1.55-1.49 (m, 1H), 1.23-1.15 (m, 2H), 0.84-0.78 (dd, 6H, J=6.4, 16 Hz). 3H (N-Me) was contained in 2.5 (DMSO)

Example 32

HL01-0 (30 mg) was dissolved in DMSO (1 mL) at RT, and N-ethyl-iminodiacetic acid (12.57 mg, 0.078 mmol) was added. The reaction mixture was stirred at 85° C. under inert gas for another 5 hrs, then cooled to RT. The solvent was removed to get solid. ¹H NMR (d₆-DMSO, 400 MHz) δ 9.12-9.08 (m 1H), 8.93-8.84 (m, 2H), 8.74-8.66 (m, 1H), 7.35-7.12 (m, 5H), 4.93-4.87 (q, 1H), 4.81-4.75 (q, 1H), 4.71-4.65 (q, 1H), 4.18-3.93 (m, 4H), 3.30-3.24 (q, 1H), 3.14-3.03 (m, 2H), 1.56-1.49 (m, 1H), 1.41-1.25 (m, 2H), 1.22-1.13 (m, 3H), 0.86-0.74 (m, 6H).

Example 33

HL01-00 (30 mg) was dissolved in ethyl acetate (1 mL) at RT, and N-methyldiethanolamine (9.87 mg, 0.083 mmol) was added, then the reaction mixture was stirred at RT under inert gas for another 5 hrs. The solvent was removed to get solid. ¹H NMR (d₆-DMSO, 400 MHz) δ 8.94-8.91 (t, 1H), 7.72 (s, 1H), 7.56-7.45 (m, 1H), 6.51-6.48 (d, 1H, J=9.6 Hz), 3.77-3.62 (m, 6H), 3.20-3.11 (m, 3H), 2.94-2.91 (m, 1H), 2.85-2.81 (m, 1H), 2.59 (s, 3H), 1.49 (s, 1H), 1.22-1.17 (m, 2H), 0.84-0.79 (dd, 6H, J=6, 16.8 Hz). MS (m/z): [M+H] calculated for C₁₉H₂₉BCl₂N₃O₄, 445.16; found, 445.4.

Example 34

HL01-00 (30 mg, 0.078 mmol) was dissolved in DMSO (1 mL) at RT, and N-ethyl-iminodiacetic acid (12.57 mg, 0.078 mmol) was added. The reaction mixture was stirred at 85° C. under inert gas for another 5 hrs, then cooled to RT, The solvent was removed to get solid. ¹H NMR (d₆-DMSO, 400 MHz) δ8.78-8.66 (dt, 1H), 7.69 (s, 1H), 7.52-7.44 (m, 2H), 7.35-7.29 (m, 1H), 4.19-3.82 (m, 6H), 3.18-3.09 (m, 2H), 2.99 (s, 1H), 1.61-1.43 (m, 1H), 1.38-1.28 (m, 2H), 1.20-1.11 (m, 3H), 0.87-0.82 (m, 6H).

In addition to the foregoing, the above reaction schemes, and variations thereof, can be used to prepare the compounds set forth in the following table:

TABLE 1 Serial # Structure Name HL-40

isopropyl (S)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4-carboxylate HL-41

isopropyl 2-((S)-2-((R)- 3-methyl-1-((S)-3- phenyl-2-(pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4-yl)acetate HL-42

tert-butyl (S)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylate HL-43

tert-butyl 2-((S)-2-((R)- 3-methyl-1-((S)-3- phenyl-2-(pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetate HL-44

ethane-1,2-diyl (4S,4′S)-bis(2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylate) HL-45

ethane-1,2-diyl bis(2- ((S)-2-((R)-3-methyl-1- ((S)-3-phenyl-2- (pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetate) HL-46

ethane-1,2-diyl bis(2- ((S)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 5-oxo-1,3,2- dioxaborolan-4- yl)acetate) HL-47

ethane-1,2-diyl bis(2- ((S)-2-((R)-1-((2S,3R)-3- hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-5-oxo- 1,3,2-dioxaborolan-4- yl)acetate) HL-48

ethane-1,2-diyl(4S,4′S)- bis(2-((R)-1-((2S,3R)-3- hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-6-oxo- 1,3,2-dioxaborinane-4- carboxylate) HL-49

ethane-1,2-diyl (4S,4′S)-bis(2-((R)-1- (2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 6-oxo-1,3,2- dioxaborinane-4- carboxylate) HL-50

tert-butyl 2-((S)-2-((R)- 1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 5-oxo-1,3,2- dioxaborolan-4- yl)acetate HL-51

(S)-tert-butyl 2-((R)-1- (2-(2,5-dichlorobenzamido) acetamido)-3-methylbutyl)- 6-oxo-1,3,2- dioxaborinane-4- carboxylate HL-52

isopropyl (S)-2-((R)-1- (2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 6-oxo-1,3,2- dioxaborinane-4- carboxylate HL-53

isopropyl 2-((S)-2-((R)- 1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 5-oxo-1,3,2- dioxaborolan-4- yl)acetate HL-54

(S)-methyl 2-((R)-1- (2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 6-oxo-1,3,2- dioxaborinane-4- carboxylate HL-55

methyl 2-((S)-2-((R)-1- (2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 5-oxo-1,3,2- dioxaborolan-4- yl)acetate HL-56

(S)-methyl 2-((R)-1- ((2S,3R)-3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-6-oxo- 1,3,2-dioxaborinane-4- carboxylate HL-57

methyl 2-((S)-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-5-oxo- 1,3,2-dioxaborolan-4- yl)acetate HL-58

(S)-isopropyl 2-((R)-1- ((2S,3R)-3- hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-6-oxo- 1,3,2-dioxaborinane-4- carboxylate HL-59

isopropyl 2-((S)-2-((R)- 1-((2S,3R)-3- hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-5-oxo- 1,3,2-dioxaborolan-4- yl)acetate HL-60

(S)-tert-butyl 2-((R)-1- ((2S,3R)-3- hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-6-oxo- 1,3,2-dioxaborinane-4- carboxylate HL-61

tert-butyl 2-((S)-2-((R)- 1-((2S,3R)-3- hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-5-oxo- 1,3,2-dioxaborolan-4- yl)acetate HL-62

N-((S)-1-(((R)-3- methyl-1-((R)-4- (methylcarbamoyl)-6- oxo-1,3,2-dioxaborinan- 2-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-63

N-((S)-1-(((R)-3- methyl-1-((R)-4-(2- (methylamino)-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-2- yl)butyl)amino)-1-oxo- 3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-64

N-((S)-1-(((R)-1-((R)-4- (isopropylcarbamoyl)- 6-oxo-1,3,2- dioxaborinan-2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-65

N-((S)-1-(((R)-1-((R)-4- (2-(isopropylamino)-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-66

N-((S)-1-(((R)-1-((R)-4- (tert-butylcarbamoyl)-6- oxo-1,3,2-dioxaborinan- 2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-67

N-((S)-1-(((R)-1-((R)-4- (2-(tert-butylamino)-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-68

N,N-ethane-1,2-diyl (4R,4′R)-bis(2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxamide) HL-69

N,N-ethane-1,2-diyl bis(2-((R)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetamide) HL-70

(R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- N-methyl-6-oxo-1,3,2- dioxaborinane-4- carboxamide HL-71

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((R)-4-(2- (methylamino)-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-2- yl)butyl)amino)-2- oxoethyl)benzamide HL-72

(R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- N-isopropyl-6-oxo- 1,3,2-dioxaborinane-4- carboxamide HL-73

2,5-dichloro-N-(2-(((R)- 1-((R)-4-(2- (isopropylamino)-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-2-yl)-3- methylbutyl)amino)-2- oxoethyl)benzamide HL-74

(R)-N-(tert-butyl)-2- ((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 6-oxo-1,3,2- dioxaborinane-4- carboxamide HL-75

N-(2-(((R)-1-((R)-4-(2- (tert-butylamino)-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-2-yl)-3- methylbutyl)amino)-2- oxoethyl)-2,5- dichlorobenzamide HL-76

(4R,4′R)-N,N′-(ethane- 1,2-diyl)bis(2- ((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 6-oxo-1,3,2- dioxaborinane-4- carboxamide) HL-77

N,N-ethane-1,2-diyl bis(2-((R)-2-((R)-1-(2- (2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 5-oxo-1,3,2- dioxaborolan-4- yl)acetamide) HL-78

N,N-ethane-1,2- diyl(4R,4′R)-bis(2-((R)- 1-((2S,3R)-3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-6-oxo- 1,3,2-dioxaborinane-4- carboxamide) HL-79

N,N-ethane-1,2-diyl (4R,4′R)-bis(2-((R)-1- ((2S,3R)-3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-6-oxo- 1,3,2-dioxaborinane-4- carboxamide) HL-80

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((R)-4- (methylcarbamoyl)-6- oxo-1,3,2-dioxaborinan- 2-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-81

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((R)-4-(2- (methylamino)-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-2- yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-82

N-((2S,3R)-3-hydroxy- 1-(((R)-1-((R)-4- (isopropylcarbamoyl)- 6-oxo-1,3,2- dioxaborinan-2-yl)-3- methylbutyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-83

N-((2S,3R)-3-hydroxy- 1-(((R)-1-((R)-4-(2- (isopropylamino)-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-2-yl)-3- methylbutyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-84

N-((2S,3R)-1-(((R)-1- ((R)-4-(tert- butylcarbamoyl)-6-oxo- 1,3,2-dioxaborinan-2- yl)-3- methylbutyl)amino)-3- hydroxy-1-oxobutan-2- yl)-6-phenylpicolinamide HL-85

N-((2S,3R)-1-(((R)-1- ((R)-4-(2-(tert- butylamino)-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-2-yl)-3- methylbutyl)amino)-3- hydroxy-1-oxobutan-2- yl)-6- phenylpicolinamide HL-86

isopropyl (R)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylate HL-87

methyl (R)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylate HL-88

methyl 2-((R)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetate HL-89

isopropyl (R)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylate HL-90

isopropyl 2-((R)-2-((R)- 3-methyl-1-((S)-3- phenyl-2-(pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetate HL-91

tert-butyl (R)-2-(R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylate HL-92

tert-butyl 2-((R)-2-((R)- 3-methyl-1-((S)-3- phenyl-2-(pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetate HL-93

ethane-1,2-diyl (4R,4′R)-bis(2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylate) HL-94

ethane-1,2-diyl (4R,4′R)-bis(2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylate) HL-95

2-((R)-4-(2-methoxy-2- oxoethyl)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-96

2-((S)-4-(2-methoxy-2- oxoethyl)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-97

(S)-4-(2-methoxy-2- oxoethyl)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-98

(R)-4-(2-methoxy-2- oxoethyl)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-99

2-((R)-4- (methoxycarbonyl)-2- ((R)-3-methyl-1-((S)-3- phenyl-2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinan-4- yl)acetic acid HL-100

2-((S)-4- (methoxycarbonyl)-2- ((R)-3-methyl-1-((S)-3- phenyl-2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinan-4- yl)acetic acid HL-101

2-((R)-4-(2-methoxy-2- oxoethyl)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-102

2-((S)-4-(2-methoxy-2- oxoethyl)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-103

(S)-4-(2-methoxy-2- oxoethyl)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-104

(R)-4-(2-methoxy-2- oxoethyl)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-105

2-((S)-4- (methoxycarbonyl)-2- ((R)-3-methyl-1-((S)-3- phenyl-2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinan-4- yl)acetic acid HL-106

2-((R)-4- (methoxycarbonyl)-2- ((R)-3-methyl-1-((S)-3- phenyl-2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinan-4- yl)acetic acid HL-107

2-((R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-methoxy-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-108

2-((S)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-methoxy-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-109

(S)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-methoxy-2- oxoethyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-110

(R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-methoxy-2- oxoethyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-111

2-((R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(methoxycarbonyl)-6- oxo-1,3,2-dioxaborinan- 4-yl)acetic acid HL-112

2-((S)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(methoxycarbonyl)-6- oxo-1,3,2-dioxaborinan- 4-yl)acetic acid HL-113

2-((R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-methoxy-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-114

2-((S)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-methoxy-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-115

(S)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-methoxy-2- oxoethyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-116

(R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-methoxy-2- oxoethyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-117

2-((S)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(methoxycarbonyl)-6- oxo-1,3,2-dioxaborinan- 4-yl)acetic acid HL-118

2-((R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(methoxycarbonyl)-6- oxo-1,3,2-dioxaborinan- 4-yl)acetic acid HL-119

2-((R)-2-((R)-1- ((2S,3R)-3-hydroxy-2-(6- phenylpicolinamide) butanamido)-3- methylbutyl)-4-(2- methoxy-2-oxoethyl)-5- oxo-1,3,2-dioxaborolan- 4-yl)acetic acid HL-120

2-((S)-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-4-(2- methoxy-2-oxoethyl)-5- oxo-1,3,2-dioxaborolan- 4-yl)acetic acid HL-121

(S)-2-((R)-1-((2S,3R)- 3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-4-(2- methoxy-2-oxoethyl)-6- oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-122

(R)-2-((R)-1-((2S,3R)- 3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-4-(2- methoxy-2-oxoethyl)-6- oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-123

2-((R)-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-4- (methoxycarbonyl)-6- oxo-1,3,2-dioxaborinan- 4-yl)acetic acid HL-124

2-((S)-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-4- (methoxycarbonyl)-6- oxo-1,3,2-dioxaborinan- 4-yl)acetic acid HL-125

2-((R)-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-4-(2- methoxy-2-oxoethyl)-5- oxo-1,3,2-dioxaborolan- 4-yl)acetic acid HL-126

2-((S)-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-4-(2- methoxy-2-oxoethyl)-5- oxo-1,3,2-dioxaborolan- 4-yl)acetic acid HL-127

(S)-2-((R)-1-((2S,3R)- 3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-4-(2- methoxy-2-oxoethyl)-6- oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-128

(R)-2-((R)-1-((2S,3R)- 3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-4-(2- methoxy-2-oxoethyl)-6- oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-129

2-((S)-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-4- (methoxycarbonyl)-6- oxo-1,3,2-dioxaborinan- 4-yl)acetic acid HL-130

2-((R)-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-4- (methoxycarbonyl)-6- oxo-1,3,2-dioxaborinan- 4-yl)acetic acid HL-131

2-((S)-2-((R)-3-methyl-1- ((S)-3-phenyl-2- (pyrazine-2- carboxamido)propanamido) butyl)-4-(2- (methylamino)-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-132

2-((R)-2-((R)-3-methyl- 1-((S)-3-phenyl-2- (pyrazine-2- carboxamido)propanamido) butyl)-4-(2- (methylamino)-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-133

(R)-2-((R)-3-methyl-1- ((S)-3-phenyl-2- (pyrazine-2- carboxamido)propanamido) butyl)-4-(2- (methylamino)-2- oxoethyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-134

(S)-2-((R)-3-methyl-1- ((S)-3-phenyl-2- (pyrazine-2- carboxamido)propanamido) butyl)-4-(2- (methylamino)-2- oxoethyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-135

2-((R)-2-((R)-3-methyl- 1-((S)-3-phenyl-2- (pyrazine-2- carboxamido)propanamido) butyl)-4- (methylcarbamoyl)-6- oxo-1,3,2-dioxaborinan- 4-yl)acetic acid HL-136

2-((S)-2-((R)-3-methyl- 1-((S)-3-phenyl-2- (pyrazine-2- carboxamido)propanamido) butyl)-4- (methylcarbamoyl)-6- oxo-1,3,2-dioxaborinan- 4-yl)acetic acid HL-137

2-((S)-2-((R)-3-methyl- 1-((S)-3-phenyl-2- (pyrazine-2- carboxamido)propanamido) butyl)-4-(2- (methylamino)-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-138

2-((R)-2-((R)-3-methyl- 1-((S)-3-phenyl-2- (pyrazine-2- carboxamido)propanamido) butyl)-4-(2- (methylamino)-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-139

(R)-2-((R)-3-methyl-1- ((S)-3-phenyl-2- (pyrazine-2- carboxamido)propanamido) butyl)-4-(2- (methylamino)-2- oxoethyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-140

(S)-2-((R)-3-methyl-1- ((S)-3-phenyl-2- (pyrazine-2- carboxamido)propanamido) butyl)-4-(2- (methylamino)-2- oxoethyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-141

2-((S)-2-((R)-3-methyl- 1-((S)-3-phenyl-2- (pyrazine-2- carboxamido)propanamido) butyl)-4- (methylcarbamoyl)-6- oxo-1,3,2-dioxaborinan- 4-yl)acetic acid HL-142

2-((R)-2-((R)-3-methyl- 1-((S)-3-phenyl-2- (pyrazine-2- carboxamido)propanamido) butyl)-4- (methylcarbamoyl)-6- oxo-1,3,2-dioxaborinan- 4-yl)acetic acid HL-143

2-((S)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-(methylamino)-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-144

2-((R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-(methylamino)-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-145

(R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-(methylamino)-2- oxoethyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-146

(S)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-(methylamino)-2- oxoethyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-147

2-((R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(methylcarbamoyl)-6- oxo-1,3,2-dioxaborinan- 4-yl)acetic acid HL-148

2-((S)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(methylcarbamoyl)-6- oxo-1,3,2-dioxaborinan- 4-yl)acetic acid HL-149

2-((S)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-(methylamino)-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-150

2-((R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-(methylamino)-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-151

(R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-(methylamino)-2- oxoethyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-152

(S)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-(methylamino)-2- oxoethyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-153

2-((S)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(methylcarbamoyl)-6- oxo-1,3,2-dioxaborinan- 4-yl)acetic acid HL-154

2-((R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(methylcarbamoyl)-6- oxo-1,3,2-dioxaborinan- 4-yl)acetic acid HL-155

2-((S)-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-4-(2- (methylamino)-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-156

2-((R)-2-((R)-1- ((2S,3R)-3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-4-(2- (methylamino)-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-157

(R)-2-((R)-1-((2S,3R)- 3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-4-(2- (methylamino)-2- oxoethyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-158

(S)-2-((R)-1-((2S,3R)- 3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-4-(2- (methylamino)-2- oxoethyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-159

2-((R)-2-((R)-1- ((2S,3R)-3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-4- (methylcarbamoyl)-6- oxo-1,3,2-dioxaborinan- 4-yl)acetic acid HL-160

2-((S)-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-4- (methylcarbamoyl)-6- oxo-1,3,2-dioxaborinan- 4-yl)acetic acid HL-161

2-((S)-2-((R)-1- ((2S,3R)-3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-4-(2- (methylamino)-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-162

2-((R)-2-((R)-1- ((2S,3R)-3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-4-(2- (methylamino)-2- oxoethyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-163

(R)-2-((R)-1-((2S,3R)- 3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-4-(2- (methylamino)-2- oxoethyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-164

(S)-2-((R)-1-((2S,3R)- 3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-4-(2- (methylamino)-2- oxoethyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-165

2-((S)-2-((R)-1- ((2S,3R)-3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-4- (methylcarbamoyl)-6- oxo-1,3,2-dioxaborinan- 4-yl)acetic acid HL-166

2-((R)-2-((R)-1- ((2S,3R)-3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-4- (methylcarbamoyl)-6- oxo-1,3,2-dioxaborinan- 4-yl)acetic acid HL-167

2-((S)-4-(2- (dimethylamino)-2- oxoethyl)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-168

2-((R)-4-(2- (dimethylamino)-2- oxoethyl)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-169

(R)-4-(2- (dimethylamino)-2- oxoethyl)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-170

(S)-4-(2- (dimethylamino)-2- oxoethyl)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-171

2-((R)-4- (dimethylcarbamoyl)-2- ((R)-3-methyl-1-((S)-3- phenyl-2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinan-4- yl)acetic acid HL-172

2-((S)-4- (dimethylcarbamoyl)-2- ((R)-3-methyl-1-((S)-3- phenyl-2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinan-4- yl)acetic acid HL-173

2-((S)-4-(2- (dimethylamino)-2- oxoethyl)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-174

2-((R)-4-(2- (dimethylamino)-2- oxoethyl)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetic acid HL-175

(R)-4-(2- (dimethylamino)-2- oxoethyl)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-176

(S)-4-(2- (dimethylamino)-2- oxoethyl)-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylic acid HL-177

2-((S)-4- (dimethylcarbamoyl)-2- ((R)-3-methyl-1-((S)-3- phenyl-2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinan-4- yl)acetic acid HL-178

2,2′-(2-((R)-3-methyl-1- ((S)-3-phenyl-2- (pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolane-4,4- diyl)bis(N,N- dimethylacetamide) HL-179

N-((S)-1-(((R)-1-((R)-4- (2-(dimethylamino)-2- oxoethyl)-4- (dimethylcarbamoyl)-6- oxo-1,3,2-dioxaborinan- 2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-180

N-((S)-1-(((R)-1-((S)-4- (2-(dimethylamino)-2- oxoethyl)-4- (dimethylcarbamoyl)-6- oxo-1,3,2-dioxaborinan- 2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-181

2-((S)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-(dimethylamino)- 2-oxoethyl)-5-oxo- 1,3,2-dioxaborolan-4- yl)acetic acid HL-182

2-((R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-(dimethylamino)- 2-oxoethyl)-5-oxo- 1,3,2-dioxaborolan-4- yl)acetic acid HL-183

(R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-(dimethylamino)- 2-oxoethyl)-6-oxo- 1,3,2-dioxaborinane-4- carboxylic acid HL-184

(S)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-(dimethylamino)- 2-oxoethyl)-6-oxo- 1,3,2-dioxaborinane-4- carboxylic acid HL-185

2-((R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(dimethylcarbamoyl)- 6-oxo-1,3,2- dioxaborinan-4- yl)acetic acid HL-186

2-((S)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(dimethylcarbamoyl)- 6-oxo-1,3,2- dioxaborinan-4- yl)acetic acid HL-187

2-((S)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-(dimethylamino)- 2-oxoethyl)-5-oxo- 1,3,2-dioxaborolan-4- yl)acetic acid HL-188

2-((R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-(dimethylamino)- 2-oxoethyl)-5-oxo- 1,3,2-dioxaborolan-4- yl)acetic acid HL-189

(R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-(dimethylamino)- 2-oxoethyl)-6-oxo- 1,3,2-dioxaborinane-4- carboxylic acid HL-190

(S)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-(dimethylamino)- 2-oxoethyl)-6-oxo- 1,3,2-dioxaborinane-4- carboxylic acid HL-191

2-((S)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(dimethylcarbamoyl)- 6-oxo-1,3,2- dioxaborinan-4- yl)acetic acid HL-192

2-((R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(dimethylcarbamoyl)- 6-oxo-1,3,2- dioxaborinan-4- yl)acetic acid HL-193

(R)-2,2′-(2-(1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 5-oxo-1,3,2- dioxaborolane-4,4- diyl)bis(N,N- dimethylacetamide) HL-194

(R)-2,2′-(2-(1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 5-oxo-1,3,2- dioxaborolane-4,4- diyl)bis(N,N- dimethylacetamide) HL-195

(R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-(dimethylamino)- 2-oxoethyl)-N,N- dimethyl-6-oxo-1,3,2- dioxaborinane-4- carboxamide HL-196

(S)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 4-(2-(dimethylamino)- 2-oxoethyl)-N,N- dimethyl-6-oxo-1,3,2- dioxaborinane-4- carboxamide HL-197

2-((S)-4-(2- (dimethylamino)-2- oxoethyl)-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-5-oxo- 1,3,2-dioxaborolan-4- yl)acetic acid HL-198

2-((R)-4-(2- (dimethylamino)-2- oxoethyl)-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-5-oxo- 1,3,2-dioxaborolan-4- yl)acetic acid HL-199

(R)-4-(2- (dimethylamino)-2- oxoethyl)-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-6-oxo- 1,3,2-dioxaborinane-4- carboxylic acid HL-200

(S)-4-(2- (dimethylamino)-2- oxoethyl)-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-6-oxo- 1,3,2-dioxaborinane-4- carboxylic acid HL-201

2-((R)-4- (dimethylcarbamoyl)-2- ((R)-1-((2S,3R)-3- hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-6-oxo- 1,3,2-dioxaborinan-4- yl)acetic acid HL-202

2-((S)-4- (dimethylcarbamoyl)-2- ((R)-1-((2S,3R)-3- hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-6-oxo- 1,3,2-dioxaborinan-4- yl)acetic acid HL-203

2-((S)-4-(2- (dimethylamino)-2- oxoethyl)-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-5-oxo- 1,3,2-dioxaborolan-4- yl)acetic acid HL-204

2-((R)-4-(2- (dimethylamino)-2- oxoethyl)-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-5-oxo- 1,3,2-dioxaborolan-4- yl)acetic acid HL-205

(R)-4-(2- (dimethylamino)-2- oxoethyl)-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-6-oxo- 1,3,2-dioxaborinane-4- carboxylic acid HL-206

(S)-4-(2- (dimethylamino)-2- oxoethyl)-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-6-oxo- 1,3,2-dioxaborinane-4- carboxylic acid HL-207

2-((S)-4- (dimethylcarbamoyl)-2- ((R)-1-((2S,3R)-3- hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-6-oxo- 1,3,2-dioxaborinan-4- yl)acetic acid HL-208

2-((R)-4- (dimethylcarbamoyl)-2- ((R)-1-((2S,3R)-3- hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-6-oxo- 1,3,2-dioxaborinan-4- yl)acetic acid HL-209

2,2′-(2-((R)-1-((2S,3R)- 3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-5-oxo- 1,3,2-dioxaborolane- 4,4-diyl)bis(N,N- dimethylacetamide) HL-210

2,2′-(2-((R)-1-((2S,3R)- 3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-5-oxo- 1,3,2-dioxaborolane- 4,4-diyl)bis(N,N- dimethylacetamide) HL-211

N-((2S,3R)-1-(((R)-1- ((R)-4-(2- (dimethylamino)-2- oxoethyl)-4- (dimethylcarbamoyl)-6- oxo-1,3,2-dioxaborinan- 2-yl)-3- methylbutyl)amino)-3- hydroxy-1-oxobutan-2- yl)-6- phenylpicolinamide HL-212

N-((2S,3R)-1-(((R)-1- ((S)-4-(2- (dimethylamino)-2- oxoethyl)-4- (dimethylcarbamoyl)-6- oxo-1,3,2-dioxaborinan- 2-yl)-3- methylbutyl)amino)-3- hydroxy-1-oxobutan-2- yl)-6- phenylpicolinamide HL-213

methyl (4R,5R)-5- hydroxy-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylate HL-214

methyl (4R,5S)-5- hydroxy-2-((R)-3- methyl-1-((S)-3-phenyl- 2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylate HL-215

methyl (R)-2-hydroxy- 2-((R)-2-((R)-3-methyl- 1-((S)-3-phenyl-2- (pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetate HL-216

methyl (R)-2-hydroxy- 2-((R)-2-((R)-3-methyl- 1-((S)-3-phenyl-2- (pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetate HL-217

methyl (4R,5R)-2-((R)- 1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 5-hydroxy-6-oxo-1,3,2- dioxaborinane-4- carboxylate HL-218

methyl (4R,5S)-2-((R)- 1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 5-hydroxy-6-oxo-1,3,2- dioxaborinane-4- carboxylate HL-219

methyl (4R,5S)-2-((R)- 1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 5-hydroxy-6-oxo-1,3,2- dioxaborinane-4- carboxylate HL-220

methyl (R)-2-((R)-2- ((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 5-oxo-1,3,2- dioxaborolan-4-yl)-2- hydroxyacetate HL-222

methyl (4R,5R)-5- hydroxy-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-6-oxo- 1,3,2-dioxaborinane-4- carboxylate HL-223

methyl (4R,5S)-5- hydroxy-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-6-oxo- 1,3,2-dioxaborinane-4- carboxylate HL-224

methyl (R)-2-hydroxy- 2-((R)-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-5-oxo- 1,3,2-dioxaborolan-4- yl)acetate HL-225

methyl (R)-2-hydroxy- 2-((R)-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-5-oxo- 1,3,2-dioxaborolan-4- yl)acetate HL-226

methyl (4R,5R)-5- amino-2-((R)-3-methyl- 1-((S)-3-phenyl-2- (pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylate HL-227

methyl (4R,5S)-5- amino-2-((R)-3-methyl- 1-((S)-3-phenyl-2- (pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylate HL-228

methyl (R)-2-amino-2- ((R)-2-((R)-3-methyl-1- ((S)-3-phenyl-2- (pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetate HL-229

methyl (R)-2-amino-2- ((R)-2-((R)-3-methyl-1- ((S)-3-phenyl-2- (pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetate HL-230

methyl (4R,5R)-5- amino-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 6-oxo-1,3,2- dioxaborinane-4- carboxylate HL-231

methyl (4R,5S)-5- amino-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 6-oxo-1,3,2- dioxaborinane-4- carboxylate HL-232

methyl (R)-2-amino-2- ((R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 5-oxo-1,3,2- dioxaborolan-4- yl)acetate HL-233

methyl (R)-2-amino-2- ((R)-2-((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 5-oxo-1,3,2- dioxaborolan-4- yl)acetate HL-234

methyl (4R,5R)-5- amino-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-6-oxo- 1,3,2-dioxaborinane-4- carboxylate HL-235

methyl (4R,5S)-5- amino-2-((R)-1- ((2S,3R)-3-hydroxy-2- (6-phenylpicolinamido) butanamido)-3- methylbutyl)-6-oxo- 1,3,2-dioxaborinane-4- carboxylate HL-236

methyl (R)-2-amino-2- ((R)-2-((R)-1-((2S,3R)- 3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-5-oxo- 1,3,2-dioxaborolan-4- yl)acetate HL-237

methyl (R)-2-amino-2- ((R)-2-((R)-1-((2S,3R)- 3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-5-oxo- 1,3,2-dioxaborolan-4- yl)acetate HL-238

methyl (4R,5R)-2-((R)- 3-methyl-1-((S)-3- phenyl-2-(pyrazine-2- carboxamido)propanamido) butyl)-5- (methylamino)-6-oxo- 1,3,2-dioxaborinane-4- carboxylate HL-239

methyl (4R,5S)-2-((R)- 3-methyl-1-((S)-3- phenyl-2-(pyrazine-2- carboxamido)propanamido) butyl)-5- (methylamino)-6-oxo- 1,3,2-dioxaborinane-4- carboxylate HL-240

methyl (R)-2-((R)-2- ((R)-3-methyl-1-((S)-3- phenyl-2-(pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4-yl)-2- (methylamino)acetate HL-241

methyl (R)-2-((R)-2- ((R)-3-methyl-1-((S)-3- phenyl-2-(pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4-yl)-2- (methylamino)acetate HL-242

methyl (4R,5R)-2-((R)- 1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 5-(methylamino)-6-oxo- 1,3,2-dioxaborinane-4- carboxylate HL-243

methyl (4R,5S)-2-((R)- 1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 5-(methylamino)-6-oxo- 1,3,2-dioxaborinane-4- carboxylate HL-244

methyl (R)-2-((R)-2- ((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 5-oxo-1,3,2- dioxaborolan-4-yl)-2- (methylamino)acetate HL-245

methyl (R)-2-((R)-2- ((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 5-oxo-1,3,2- dioxaborolan-4-yl)-2- (methylamino)acetate HL-246

methyl (4R,5R)-2-((R)- 1-((2S,3R)-3-hydroxy- 2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-5- (methylamino)-6-oxo- 1,3,2-dioxaborinane-4- carboxylate HL-247

methyl (4R,5S)-2-((R)- 1-((2S,3R)-3-hydroxy- 2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-5- (methylamino)-6-oxo- 1,3,2-dioxaborinane-4- carboxylate HL-248

methyl (R)-2-((R)-2- ((R)-1-((2S,3R)-3- hydroxy-2-(6 phenylpicolinamido) butanamido)-3- methylbutyl)-5-oxo- 1,3,2-dioxaborolan-4- yl)-2- (methylamino)acetate HL-249

methyl (R)-2-((R)-2- ((R)-1-((2S,3R)-3- hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-5-oxo- 1,3,2-dioxaborolan-4- yl)-2- (methylamino)acetate HL-250

methyl (4R,5R)-5- (dimethylamino)-2- ((R)-1-((2S,3R)-3- hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-6-oxo- 1,3,2-dioxaborinane-4- carboxylate HL-251

methyl (4R,5S)-5- (dimethylamino)-2- ((R)-1-((2S,3R)-3- hydroxy-2-(6 phenylpicolinamido) butanamido)-3- methylbutyl)-6-oxo- 1,3,2-dioxaborinane-4- carboxylate HL-252

methyl (R)-2- (dimethylamino)-2- ((R)-2-((R)-1-((2S,3R)- 3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-5-oxo- 1,3,2-dioxaborolan-4- yl)acetate HL-253

methyl (R)-2- (dimethylamino)-2- ((R)-2-((R)-1-((2S,3R)- 3-hydroxy-2-(6- phenylpicolinamido) butanamido)-3- methylbutyl)-5-oxo- 1,3,2-dioxaborolan-4- yl)acetate HL-254

methyl (4R,5R)-2-((R)- 1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 5-(dimethylamino)-6- oxo-1,3,2- dioxaborinane-4- carboxylate HL-255

methyl (4R,5S)-2-((R)- 1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 5-(dimethylamino)-6- oxo-1,3,2- dioxaborinane-4- carboxylate HL-256

methyl (R)-2-((R)-2- ((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 5-oxo-1,3,2- dioxaborolan-4-yl)-2- (dimethylamino)acetate HL-257

methyl (R)-2-((R)-2- ((R)-1-(2-(2,5- dichlorobenzamido) acetamido)-3-methylbutyl)- 5-oxo-1,3,2- dioxaborolan-4-yl)-2- (dimethylamino)acetate HL-258

methyl (4R,5R)-5- (dimethylamino)-2- ((R)-3-methyl-1-((S)-3- phenyl-2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylate HL-259

methyl (4R,5S)-5- (dimethylamino)-2- ((R)-3-methyl-1-((S)-3- phenyl-2-(pyrazine-2- carboxamido)propanamido) butyl)-6-oxo-1,3,2- dioxaborinane-4- carboxylate HL-260

methyl (R)-2- (dimethylamino)-2- ((R)-2-(R)-3-methyl-1- ((S)-3-phenyl-2- (pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetate HL-261

methyl (R)-2- (dimethylamino)-2- ((R)-2-((R)-3-methyl-1- ((S)-3-phenyl-2- (pyrazine-2- carboxamido)propanamido) butyl)-5-oxo-1,3,2- dioxaborolan-4- yl)acetate HL-262

N-((S)-1-(((R)-1-((R)- 5,6-dimethyl-4,8-dioxo- 1,3,6,2-dioxazaborocan- 2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-263

2,5-dichloro-N-(2-(((R)- 1-((R)-5,6-dimethyl- 4,8-dioxo-1,3,6,2- dioxazaborocan-2-yl)-3- methylbutyl)amino)-2- oxoethyl)benzamide HL-264

N-((2S,3R)-1-(((R)-1- ((R)-5,6-dimethyl-4,8- dioxo-1,3,6,2- dioxazaborocan-2-yl)-3- methylbutyl)amino)-3- hydroxy-1-oxobutan-2- yl)-6- phenylpicolinamide HL-265

N-((S)-1-(((R)-1-((R)- 5,6-dimethyl-4,8-dioxo- 1,3,6,2-dioxazaborocan- 2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-266

2,5-dichloro-N-(2-(((R)- 1-((R)-5,6-dimethyl- 4,8-dioxo-1,3,6,2- dioxazaborocan-2-yl)-3- methylbutyl)amino)-2- oxoethyl)benzamide HL-267

N-((2S,3R)-1-(((R)-1- ((R)-5,6-dimethyl-4,8- dioxo-1,3,6,2- dioxazaborocan-2-yl)-3- methylbutyl)amino)-3- hydroxy-1-oxobutan-2- yl)-6- phenylpicolinamide HL-268

N-((S)-1-(((R)-3- methyl-1-((5R,7R)- 5,6,7-trimethyl-4,8- dioxo-1,3,6,2- dioxazaborocan-2- yl)butyl)amino)-1-oxo- 3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-269

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((5R,7R)- 5,6,7-trimethyl-4,8- dioxo-1,3,6,2- dioxazaborocan-2- yl)butyl)amino)-2- oxoethyl)benzamide HL-270

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((5R,7R)-5,6,7- trimethyl-4,8-dioxo- 1,3,6,2-dioxazaborocan- 2-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-271

N-((S)-1-(((R)-3- methyl-1-((5R,7S)- 5,6,7-trimethyl-4,8- dioxo-1,3,6,2- dioxazaborocan-2- yl)butyl)amino)-1-oxo- 3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-272

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((5R,7S)- 5,6,7-trimethyl-4,8- dioxo-1,3,6,2- dioxazaborocan-2- yl)butyl)amino)-2- oxoethyl)benzamide HL-273

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((5R,7S)-5,6,7- trimethyl-4,8-dioxo- 1,3,6,2-dioxazaborocan- 2-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-274

N-((S)-1-(((R)-3- methyl-1-((5R,7R)- 5,6,7-trimethyl-4,8- dioxo-1,3,6,2- dioxazaborocan-2- yl)butyl)amino)-1-oxo- 3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-275

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((5R,7R)- 5,6,7-trimethyl-4,8- dioxo-1,3,6,2- dioxazaborocan-2- yl)butyl)amino)-2- oxoethyl)benzamide HL-276

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((5R,7R)-5,6,7- trimethyl-4,8-dioxo- 1,3,6,2-dioxazaborocan- 2-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-277

N-((S)-1-(((R)-3- methyl-1-((5R,7S)- 5,6,7-trimethyl-4,8- dioxo-1,3,6,2- dioxazaborocan-2- yl)butyl)amino)-1-oxo- 3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-278

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((5R,7S)- 5,6,7-trimethyl-4,8- dioxo-1,3,6,2- dioxazaborocan-2- yl)butyl)amino)-2- oxoethyl)benzamide HL-279

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((5R,7S)-5,6,7- trimethyl-4,8-dioxo- 1,3,6,2-dioxazaborocan- 2-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-280

N-((S)-1-(((R)-3- methyl-1-((1R,7S)-11- methyl-2,6-dioxo-3,5- dioxa-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-281

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1R,7S)- 11-methyl-2,6-dioxo- 3,5-dioxa-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-282

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1R,7S)-11-methyl- 2,6-dioxo-3,5-dioxa-11- aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6 phenylpicolinamide HL-283

N-((S)-1-(((R)-3- methyl-1-((1R,7R)-11- methyl-2,6-dioxo-3,5- dioxa-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-284

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1R,7R)- 11-methyl-2,6-dioxo- 3,5-dioxa-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-285

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1R,7R)-11-methyl- 2,6-dioxo-3,5-dioxa-11- aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-286

N-((S)-1-(((R)-3- methyl-1-((1S,7S)-11- methyl-2,6-dioxo-3,5- dioxa-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-287

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1S,7S)-11- methyl-2,6-dioxo-3,5- dioxa-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-288

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1S,7S)-11-methyl-2,6- dioxo-3,5-dioxa-11-aza- 4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-289

N-((S)-1-(((R)-3- methyl-1-((1R,7S)-11- methyl-2,6-dioxo-3,5- dioxa-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-290

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1R,7S)- 11-methyl-2,6-dioxo- 3,5-dioxa-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-291

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1R,7S)-11-methyl- 2,6-dioxo-3,5-dioxa-11- aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-292

N-((S)-1-(((R)-3- methyl-1-((1R,7S)-11- methyl-2,6-dioxo-3,5,9- trioxa-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-293

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1R,7S)- 11-methyl-2,6-dioxo- 3,5,9-trioxa-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-294

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1R,7S)-11-methyl- 2,6-dioxo-3,5,9-trioxa- 11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-295

N-((S)-1-(((R)-3- methyl-1-((1R,7R)-11- methyl-2,6-dioxo-3,5,9- trioxa-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-296

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1R,7R)- 11-methyl-2,6-dioxo- 3,5,9-trioxa-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-297

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1R,7R)-11-methyl- 2,6-dioxo-3,5,9-trioxa- 11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-298

N-((S)-1-(((R)-3- methyl-1-((1S,7S)-11- methyl-2,6-dioxo-3,5,9- trioxa-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-299

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1S,7S)-11- methyl-2,6-dioxo-3,5,9- trioxa-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-300

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1S,7S)-11-methyl-2,6- dioxo-3,5,9-trioxa-11- aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-301

N-((S)-1-(((R)-3- methyl-1-((1R,7S)-11- methyl-2,6-dioxo-3,5,9- trioxa-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-302

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1R,7S)- 11-methyl-2,6-dioxo- 3,5,9-trioxa-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-303

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1R,7S)-11-methyl- 2,6-dioxo-3,5,9-trioxa- 11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-304

N-((S)-1-(((R)-3- methyl-1-((1R,7S)-11- methyl-2,6-dioxo-3,5- dioxa-9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-305

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1R,7S)- 11-methyl-2,6-dioxo- 3,5-dioxa-9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-306

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1R,7S)-11-methyl- 2,6-dioxo-3,5-dioxa- 9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-307

N-((S)-1-(((R)-3- methyl-1-((1R,7R)-11- methyl-2,6-dioxo-3,5- dioxa-9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-308

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1R,7R)- 11-methyl-2,6-dioxo- 3,5-dioxa-9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-309

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1R,7R)-11-methyl- 2,6-dioxo-3,5-dioxa- 9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-310

N-((S)-1-(((R)-3- methyl-1-((1S,7S)-11- methyl-2,6-dioxo-3,5- dioxa-9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-311

2,5-dichloro-N-(2- (((R)-3-methyl-1- ((1S,7S)-11-methyl-2,6- dioxo-3,5-dioxa-9,11- diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-312

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1S,7S)-11-methyl-2,6- dioxo-3,5-dioxa-9,11- diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-313

N-((S)-1-(((R)-3- methyl-1-((1R,7S)-11- methyl-2,6-dioxo-3,5- dioxa-9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-314

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1R,7S)- 11-methyl-2,6-dioxo- 3,5-dioxa-9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-315

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1R,7S)-11-methyl- 2,6-dioxo-3,5-dioxa- 9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-316

N-((S)-1-(((R)-3- methyl-1-((1R,7S)-11- methyl-2,6-dioxo-3,5- dioxa-9-thia-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-317

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1R,7S)- 11-methyl-2,6-dioxo- 3,5-dioxa-9-thia-11-aza- 4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-318

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1R,7S)-11-methyl- 2,6-dioxo-3,5-dioxa-9- thia-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-319

N-((S)-1-(((R)-3- methyl-1-((1S,7S)-11- methyl-2,6-dioxo-3,5- dioxa-9-thia-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-320

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1S,7S)-11- methyl-2,6-dioxo-3,5- dioxa-9-thia-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-321

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1S,7S)-11-methyl-2,6- dioxo-3,5-dioxa-9-thia- 11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-322

N-((S)-1-(((R)-3- methyl-1-((1R,7R)-11- methyl-2,6-dioxo-3,5- dioxa-9-thia-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-323

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1R,7R)- 11-methyl-2,6-dioxo- 3,5-dioxa-9-thia-11-aza- 4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-324

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1R,7R)-11-methyl- 2,6-dioxo-3,5-dioxa-9- thia-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-325

N-((S)-1-(((R)-3- methyl-1-((1R,7S)-11- methyl-2,6-dioxo-3,5- dioxa-9-thia-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-326

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1R,7S)- 11-methyl-2,6-dioxo- 3,5-dioxa-9-thia-11-aza- 4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-327

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1R,7S)-11-methyl- 2,6-dioxo-3,5-dioxa-9- thia-11-aza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-328

N-((S)-1-(((R)-3- methyl-1-((1R,7R)-10- methyl-2,6-dioxo-3,5- dioxa-10-aza-4- borabicyclo[5.2.1]decan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-329

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1R,7R)- 10-methyl-2,6-dioxo- 3,5-dioxa-10-aza-4- borabicyclo[5.2.1]decan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-330

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1R,7R)-10-methyl- 2,6-dioxo-3,5-dioxa-10- aza-4- borabicyclo[5.2.1]decan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-331

N-((S)-1-(((R)-3- methyl-1-((1R,7S)-10- methyl-2,6-dioxo-3,5- dioxa-10-aza-4- borabicyclo[5.2.1]decan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-332

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1R,7S)- 10-methyl-2,6-dioxo- 3,5-dioxa-10-aza-4- borabicyclo[5.2.1]decan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-333

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1R,7S)-10-methyl- 2,6-dioxo-3,5-dioxa-10- aza-4- borabicyclo[5.2.1]decan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-334

N-((S)-1-(((R)-3- methyl-1-((1R,7S)-10- methyl-2,6-dioxo-3,5- dioxa-10-aza-4- borabicyclo[5.2.1]decan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-335

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1R,7S)- 10-methyl-2,6-dioxo- 3,5-dioxa-10-aza-4- borabicyclo[5.2.1]decan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-336

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1R,7S)-10-methyl- 2,6-dioxo-3,5-dioxa-10- aza-4- borabicyclo[5.2.1]decan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-337

N-((S)-1-(((R)-3- methyl-1-((1S,7S)-10- methyl-2,6-dioxo-3,5- dioxa-10-aza-4- borabicyclo[5.2.1]decan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-338

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1S,7S)-10- methyl-2,6-dioxo-3,5- dioxa-10-aza-4- borabicyclo[5.2.1]decan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-339

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1R,7S)-10-methyl- 2,6-dioxo-3,5-dioxa-10- aza-4- borabicyclo[5.2.1]decan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-340

N-((S)-1-(((R)-1- ((1R,7S)-9,11-dimethyl- 2,6-dioxo-3,5-dioxa- 9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-341

2,5-dichloro-N-(2-(((R)- 1-((1R,7S)-9,11- dimethyl-2,6-dioxo-3,5- dioxa-9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)-3- methylbutyl)amino)-2- oxoethyl)benzamide HL-342

N-((2S,3R)-1-(((R)-1- ((1R,7S)-9,11-dimethyl- 2,6-dioxo-3,5-dioxa- 9,11-diaza-4- borabicyclo[5.3.1]undecan- an-4-yl)-3- methylbutyl)amino)-3- hydroxy-1-oxobutan-2- yl)-6- phenylpicolinamide HL-343

N-((S)-1-(((R)-1- ((1R,7R)-9,11- dimethyl-2,6-dioxo-3,5- dioxa-9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-344

2,5-dichloro-N-(2-(((R)- 1-((1R,7R)-9,11- dimethyl-2,6-dioxo-3,5- dioxa-9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)-3- methylbutyl)amino)-2- oxoethyl)benzamide HL-345

N-((2S,3R)-1-(((R)-1- ((1R,7R)-9,11- dimethyl-2,6-dioxo-3,5- dioxa-9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)-3- methylbutyl)amino)-3- hydroxy-1-oxo-3- phenylpropan-2-yl)-6- phenylpicolinamide HL-346

N-((S)-1-(((R)-1- ((1S,7S)-9,11-dimethyl- 2,6-dioxo-3,5-dioxa- 9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-347

2,5-dichloro-N-(2-(((R)- 1-((1S,7S)-9,11- dimethyl-2,6-dioxo-3,5- dioxa-9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)-3- methylbutyl)amino)-2- oxoethyl)benzamide HL-348

N-((2S,3R)-1-(((R)-1- ((1S,7S)-9,11-dimethyl- 2,6-dioxo-3,5-dioxa- 9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)-3- methylbutyl)amino)-3- hydroxy-1-oxobutan- 2-yl)-6- phenylpicolinamide HL-349

N-((S)-1-(((R)-1- ((1R,7S)-9,11-dimethyl- 2,6-dioxo-3,5-dioxa- 9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-350

2,5-dichloro-N-(2-(((R)- 1-((1R,7S)-9,11- dimethyl-2,6-dioxo-3,5- dioxa-9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)-3- methylbutyl)amino)-2- oxoethyl)benzamide HL-351

N-((2S,3R)-1-(((R)-1- ((1R,7S)-9,11-dimethyl- 2,6-dioxo-3,5-dioxa- 9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)-3- methylbutyl)amino)-3- hydroxy-1-oxobutan-2- yl)-6- phenylpicolinamide HL-352

N-((S)-1-(((R)-3- methyl-1-((1R,7S)-11- methyl-2,6-dioxo-9- phenyl-3,5-dioxa-9,11- diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-353

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1R,7S)- 11-methyl-2,6-dioxo-9- phenyl-3,5-dioxa-9,11- diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-354

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1R,7S)-11-methyl- 2,6-dioxo-9-phenyl-3,5- dioxa-9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-355

N-((S)-1-(((R)-3- methyl-1-((1R,7R)-11- methyl-2,6-dioxo-9- phenyl-3,5-dioxa-9,11- diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-356

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1R,7R)- 11-methyl-2,6-dioxo-9- phenyl-3,5-dioxa-9,11- diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-357

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1R,7R)-11-methyl- 2,6-dioxo-9-phenyl-3,5- dioxa-9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-358

N-((S)-1-(((R)-3- methyl-1-((1S,7S)-11- methyl-2,6-dioxo-9- phenyl-3,5-dioxa-9,11- diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-359

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1S,7S)-11- methyl-2,6-dioxo-9- phenyl-3,5-dioxa-9,11- diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-360

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1S,7S)-11-methyl-2,6- dioxo-9-phenyl-3,5- dioxa-9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-361

N-((S)-1-(((R)-3- methyl-1-((1R,7S)-11- methyl-2,6-dioxo-9- phenyl-3,5-dioxa-9,11- diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-362

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((1R,7S)- 11-methyl-2,6-dioxo-9- phenyl-3,5-dioxa-9,11- diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-2- oxoethyl)benzamide HL-363

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((1R,7S)-11-methyl- 2,6-dioxo-9-phenyl-3,5- dioxa-9,11-diaza-4- borabicyclo[5.3.1]undecan- 4-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-364

N-((S)-1-(((R)-1-(4,8- dioxo-1,3,6,2- trioxaborocan-2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-365

(R)-2,5-dichloro-N-(2- ((1-(4,8-dioxo-1,3,6,2- trioxaborocan-2-yl)-3- methylbutyl)amino)-2- oxoethyl)benzamide HL-366

N-((2S,3R)-1-(((R)-1- (4,8-dioxo-1,3,6,2- trioxaborocan-2-yl)-3- methylbutyl)amino)-3- hydroxy-1-oxobutan-2- yl)-6- phenylpicolinamide HL-367

N-((S)-1-(((R)-3- methyl-1-((R)-5- methyl-4,8-dioxo- 1,3,6,2-trioxaborocan-2- yl)butyl)amino)-1-oxo- 3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-368

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((R)-5- methyl-4,8-dioxo- 1,3,6,2-trioxaborocan-2- yl)butyl)amino)-2- oxoethyl)benzamide HL-369

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((R)-5-methyl-4,8- dioxo-1,3,6,2- trioxaborocan-2- yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-370

N-((S)-1-(((R)-3- methyl-1-((R)-5- methyl-4,8-dioxo- 1,3,6,2-trioxaborocan-2- yl)butyl)amino)-1-oxo- 3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-371

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((R)-5- methyl-4,8-dioxo- 1,3,6,2-trioxaborocan-2- yl)butyl)amino)-2- oxoethyl)benzamide HL-372

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((R)-5-methyl-4,8- dioxo-1,3,6,2- trioxaborocan-2- yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-373

N-((S)-1-(((R)-1- ((5R,7S)-5,7-dimethyl- 4,8-dioxo-1,3,6,2- trioxaborocan-2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-374

2,5-dichloro-N-(2-(((R)- 1-((5R,7S)-5,7- dimethyl-4,8-dioxo- 1,3,6,2-trioxaborocan-2- yl)-3- methylbutyl)amino)-2- oxoethyl)benzamide HL-375

N-((2S,3R)-1-(((R)-1- ((5R,7S)-5,7-dimethyl- 4,8-dioxo-1,3,6,2- trioxaborocan-2-yl)-3- methylbutyl)amino)-3- hydroxy-1-oxobutan-2- yl)-6- phenylpicolinamide HL-376

N-((S)-1-(((R)-1- ((5R,7R)-5,7-dimethyl- 4,8-dioxo-1,3,6,2- trioxaborocan-2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-377

2,5-dichloro-N-(2-(((R)- 1-((5R,7R)-5,7- dimethyl-4,8-dioxo- 1,3,6,2-trioxaborocan-2- yl)-3- methylbutyl)amino)-2- oxoethyl)benzamide HL-378

N-((2S,3R)-1-(((R)-1- ((5R,7R)-5,7-dimethyl- 4,8-dioxo-1,3,6,2- trioxaborocan-2-yl)-3- methylbutyl)amino)-3- hydroxy-1-oxobutan-2- yl)-6- phenylpicolinamide HL-379

N-((S)-1-(((R)-1- ((5R,7S)-5,7-dimethyl- 4,8-dioxo-1,3,6,2- trioxaborocan-2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-380

2,5-dichloro-N-(2-(((R)- 1-((5R,7S)-5,7- dimethyl-4,8-dioxo- 1,3,6,2-trioxaborocan-2- yl)-3- methylbutyl)amino)-2- oxoethyl)benzamide HL-381

N-((2S,3R)-1-(((R)-1- ((5R,7S)-5,7-dimethyl- 4,8-dioxo-1,3,6,2- trioxaborocan-2-yl)-3- methylbutyl)amino)-3- hydroxy-1-oxobutan-2- yl)-6- phenylpicolinamide HL-382

N-((S)-1-(((R)-1- ((5R,7R)-5,7-dimethyl- 4,8-dioxo-1,3,6,2- trioxaborocan-2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-383

2,5-dichloro-N-(2-(((R)- 1-((5R,7R)-5,7- dimethyl-4,8-dioxo- 1,3,6,2-trioxaborocan-2- yl)-3- methylbutyl)amino)-2- oxoethyl)benzamide HL-384

N-((2S,3R)-1-(((R)-1- ((5R,7R)-5,7-dimethyl- 4,8-dioxo-1,3,6,2- trioxaborocan-2-yl)-3- methylbutyl)amino)-3- hydroxy-1-oxobutan-2- yl)-6- phenylpicolinamide HL-385

N-((S)-1-(((R)-1-(4,8- dioxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 1-oxo-3-phenylpropan- 2-yl)pyrazine-2- carboxamide HL-386

(R)-2,5-dichloro-N-(2- ((1-(4,8-dioxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 2-oxoethyl)benzamide HL-387

N-((2S,3R)-1-(((R)-1- (4,8-dioxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 3-hydroxy-1-oxobutan- 2-yl)-6- phenylpicolinamide HL-388

N-((S)-1-(((R)-3- methyl-1-((R)-5- methyl-4,8-dioxo- 1,3,6,2- dioxathiaborocan-2- yl)butyl)amino)-1-oxo- 3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-389

2,5-dichloro-N-((S)-1- (((R)-3-methyl-1-((R)- 5-methyl-4,8-dioxo- 1,3,6,2- dioxathiaborocan-2- yl)butyl)amino)-1-oxo- 3-phenylpropan-2- yl)benzamide HL-390

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((R)-5-methyl-4,8- dioxo-1,3,6,2- dioxathiaborocan-2- yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-391

N-((S)-1-(((R)-3- methyl-1-((R)-5- methyl-4,8-dioxo- 1,3,6,2- dioxathiaborocan-2- yl)butyl)amino)-1-oxo- 3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-392

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((R)-5- methyl-4,8-dioxo- 1,3,6,2- dioxathiaborocan-2- yl)butyl)amino)-2- oxoethyl)benzamide HL-393

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((R)-5-methyl-4,8- dioxo-1,3,6,2- dioxathiaborocan-2- yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-394

N-((S)-1-(((R)-1- ((5R,7S)-5,7-dimethyl- 4,8-dioxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 1-oxo-3-phenylpropan- 2-yl)pyrazine-2- carboxamide HL-395

2,5-dichloro-N-(2-(((R)- 1-((5R,7S)-5,7- dimethyl-4,8-dioxo- 1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 2-oxoethyl)benzamide HL-396

N-((2S,3R)-1-(((R)-1- ((5R,7S)-5,7-dimethyl- 4,8-dioxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 3-hydroxy-1-oxobutan- 2-yl)-6- phenylpicolinamide HL-397

N-((S)-1-(((R)-1- ((5R,7R)-5,7-dimethyl- 4,8-dioxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 1-oxo-3-phenylpropan- 2-yl)pyrazine-2- carboxamide HL-398

2,5-dichloro-N-(2-(((R)- 1-((5R,7R)-5,7- dimethyl-4,8-dioxo- 1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 2-oxoethyl)benzamide HL-399

N-((2S,3R)-1-(((R)-1- ((5R,7R)-5,7-dimethyl- 4,8-dioxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 3-hydroxy-1-oxobutan- 2-yl)-6- phenylpicolinamide HL-400

N-((S)-1-(((R)-1- ((5R,7S)-5,7-dimethyl- 4,8-dioxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 1-oxo-3-phenylpropan- 2-yl)pyrazine-2- carboxamide HL-401

2,5-dichloro-N-(2-(((R)- 1-((5R,7S)-5,7- dimethyl-4,8-dioxo- 1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 2-oxoethyl)benzamide HL-402

N-((2S,3R)-1-(((R)-1- ((5R,7S)-5,7-dimethyl- 4,8-dioxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 3-hydroxy-1-oxobutan- 2-yl)-6- phenylpicolinamide HL-403

N-((S)-1-(((R)-1- ((5R,7R)-5,7-dimethyl- 4,8-dioxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 1-oxo-3-phenylpropan- 2-yl)pyrazine-2- carboxamide HL-404

2,5-dichloro-N-(2-(((R)- 1-((5R,7R)-5,7- dimethyl-4,8-dioxo- 1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 2-oxoethyl)benzamide HL-405

N-((2S,3R)-1-(((R)-1- ((5R,7R)-5,7-dimethyl- 4,8-dioxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 3-hydroxy-1-oxobutan- 2-yl)-6- phenylpicolinamide HL-406

N-((S)-1-(((R)-3- methyl-1-(4-oxo- 1,3,6,2- dioxathiaborocan-2- yl)butyl)amino)-1-oxo- 3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-407

(R)-2,5-dichloro-N-(2- ((3-methyl-1-(4-oxo- 1,3,6,2- dioxathiaborocan-2- yl)butyl)amino)-2- oxoethyl)benzamide HL-408

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1-(4- oxo-1,3,6,2- dioxathiaborocan-2- yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-409

N-((S)-1-(((R)-3- methyl-1-((R)-7- methyl-4-oxo-1,3,6,2- dioxathiaborocan-2- yl)butyl)amino)-1-oxo- 3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-410

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((R)-7- methyl-4-oxo-1,3,6,2- dioxathiaborocan-2- yl)butyl)amino)-2- oxoethyl)benzamide HL-411

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((R)-7-methyl-4-oxo- 1,3,6,2- dioxathiaborocan-2- yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-412

N-((S)-1-(((R)-3- methyl-1-((R)-7- methyl-4-oxo-1,3,6,2- dioxathiaborocan-2- yl)butyl)amino)-1-oxo- 3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-413

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((R)-5- methyl-4,8-dioxo- 1,3,6,2- dioxathiaborocan-2- yl)butyl)amino)-2- oxoethyl)benzamide HL-414

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((R)-5-methyl-4,8- dioxo-1,3,6,2- dioxathiaborocan-2- yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-415

N-((S)-1-(((R)-1- ((5S,7R)-5,7-dimethyl- 4-oxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 1-oxo-3-phenylpropan- 2-yl)pyrazine-2- carboxamide HL-416

2,5-dichloro-N-(2-(((R)- 1-((5S,7R)-5,7- dimethyl-4-oxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 2-oxoethyl)benzamide HL-417

N-((2S,3R)-1-(((R)-1- ((5S,7R)-5,7-dimethyl- 4-oxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 3-hydroxy-1-oxobutan- 2-yl)-6- phenylpicolinamide HL-418

N-((S)-1-(((R)-1- ((5R,7R)-5,7-dimethyl- 4-oxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 1-oxo-3-phenylpropan- 2-yl)pyrazine-2- carboxamide HL-419

2,5-dichloro-N-(2-(((R)- 1-((5R,7R)-5,7- dimethyl-4-oxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 2-oxoethyl)benzamide HL-420

N-((2S,3R)-1-(((R)-1- ((5R,7R)-5,7-dimethyl- 4-oxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 3-hydroxy-1-oxobutan- 2-yl)-6- phenylpicolinamide HL-421

N-((S)-1-(((R)-1- ((5S,7R)-5,7-dimethyl- 4-oxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 1-oxo-3-phenylpropan- 2-yl)pyrazine-2- carboxamide HL-422

2,5-dichloro-N-(2-(((R)- 1-((5S,7R)-5,7- dimethyl-4-oxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 2-oxoethyl)benzamide HL-423

N-((2S,3R)-1-(((R)-1- ((5S,7R)-5,7-dimethyl- 4-oxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 3-hydroxy-1-oxobutan- 2-yl)-6- phenylpicolinamide HL-424

N-((S)-1-(((R)-1- ((5R,7R)-5,7-dimethyl- 4-oxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 1-oxo-3-phenylpropan- 2-yl)pyrazine-2- carboxamide HL-425

2,5-dichloro-N-(2-(((R)- 1-((5R,7R)-5,7- dimethyl-4-oxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 2-oxoethyl)benzamide HL-426

N-((2S,3R)-1-(((R)-1- ((5R,7R)-5,7-dimethyl- 4-oxo-1,3,6,2- dioxathiaborocan-2-yl)- 3-methylbutyl)amino)- 3-hydroxy-1-oxobutan- 2-yl)-6- phenylpicolinamide HL-427

N-((S)-1-(((R)-3- methyl-1-(4-oxo- 1,3,6,2-dioxazaborocan- 2-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-428

(R)-2,5-dichloro-N-(2- ((3-methyl-1-(4-oxo- 1,3,6,2-dioxazaborocan- 2-yl)butyl)amino)-2- oxoethyl)benzamide HL-429

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1-(4- oxo-1,3,6,2- dioxazaborocan-2- yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-430

N-((S)-1-(((R)-3- methyl-1-((R)-7- methyl-4-oxo-1,3,6,2- dioxazaborocan-2- yl)butyl)amino)-1-oxo- 3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-431

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((R)-7- methyl-4-oxo-1,3,6,2- dioxazaborocan-2- yl)butyl)amino)-2- oxoethyl)benzamide HL-432

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((R)-7-methyl-4-oxo- 1,3,6,2-dioxazaborocan- 2-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-433

N-((S)-1-(((R)-3- methyl-1-((R)-7- methyl-4-oxo-1,3,6,2- dioxazaborocan-2- yl)butyl)amino)-1-oxo- 3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-434

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((R)-5- methyl-4,8-dioxo- 1,3,6,2-dioxazaborocan- 2-yl)butyl)amino)-2- oxoethyl)benzamide HL-435

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((R)-5-methyl-4,8- dioxo-1,3,6,2- dioxazaborocan-2- yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-436

N-((S)-1-(((R)-1- ((5S,7R)-5,7-dimethyl- 4-oxo-1,3,6,2- dioxazaborocan-2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-437

2,5-dichloro-N-(2-(((R)- 1-((5S,7R)-5,7- dimethyl-4-oxo-1,3,6,2- dioxazaborocan-2-yl)-3- methylbutyl)amino)-2- oxoethyl)benzamide HL-438

N-((2S,3R)-1-(((R)-1- ((5S,7R)-5,7-dimethyl- 4-oxo-1,3,6,2- dioxazaborocan-2-yl)-3- methylbutyl)amino)-3- hydroxy-1-oxobutan-2- yl)-6- phenylpicolinamide HL-439

N-((S)-1-(((R)-1- ((5R,7R)-5,7-dimethyl- 4-oxo-1,3,6,2- dioxazaborocan-2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-440

2,5-dichloro-N-(2-(((R)- 1-((5R,7R)-5,7- dimethyl-4-oxo-1,3,6,2- dioxazaborocan-2-yl)-3- methylbutyl)amino)-2- oxoethyl)benzamide HL-441

N-((2S,3R)-1-(((R)-1- ((5R,7R)-5,7-dimethyl- 4-oxo-1,3,6,2- dioxazaborocan-2-yl)-3- methylbutyl)amino)-3- hydroxy-1-oxobutan-2- yl)-6- phenylpicolinamide HL-442

N-((S)-1-(((R)-1- ((5S,7R)-5,7-dimethyl- 4-oxo-1,3,6,2- dioxazaborocan-2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-443

2,5-dichloro-N-(2-(((R)- 1-((5S,7R)-5,7- dimethyl-4-oxo-1,3,6,2- dioxazaborocan-2-yl)-3- methylbutyl)amino)-2- oxoethyl)benzamide HL-444

N-((2S,3R)-1-(((R)-1- ((5S,7R)-5,7-dimethyl- 4-oxo-1,3,6,2- dioxazaborocan-2-yl)-3- methylbutyl)amino)-3- hydroxy-1-oxobutan-2- yl)-6- phenylpicolinamide HL-445

N-((S)-1-(((R)-1- ((5R,7R)-5,7-dimethyl- 4-oxo-1,3,6,2- dioxazaborocan-2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-446

2,5-dichloro-N-(2-(((R)- 1-((5R,7R)-5,7- dimethyl-4-oxo-1,3,6,2- dioxazaborocan-2-yl)-3- methylbutyl)amino)-2- oxoethyl)benzamide HL-447

N-((2S,3R)-1-(((R)-1- ((5R,7R)-5,7-dimethyl- 4-oxo-1,3,6,2- dioxazaborocan-2-yl)-3- methylbutyl)amino)-3- hydroxy-1-oxobutan-2- yl)-6- phenylpicolinamide HL-448

N-((S)-1-(((R)-3- methyl-1-(6-methyl-4- oxo-1,3,6,2- dioxazaborocan-2- yl)butyl)amino)-1-oxo- 3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-449

(R)-2,5-dichloro-N-(2- ((3-methyl-1-(6-methyl- 4-oxo-1,3,6,2- dioxazaborocan-2- yl)butyl)amino)-2- oxoethyl)benzamide HL-450

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1-(6- methyl-4-oxo-1,3,6,2- dioxazaborocan-2- yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-451

N-((S)-1-(((R)-1-((R)- 6,7-dimethyl-4-oxo- 1,3,6,2-dioxazaborocan- 2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-452

2,5-dichloro-N-(2-(((R)- 1-((R)-6,7-dimethyl-4- oxo-1,3,6,2- dioxazaborocan-2-yl)-3- methylbutyl)amino)-2- oxoethyl)benzamide HL-453

N-((2S,3R)-1-(((R)-1- ((R)-6,7-dimethyl-4- oxo-1,3,6,2- dioxazaborocan-2-yl)-3- methylbutyl)amino)-3- hydroxy-1-oxobutan-2- yl)-6- phenylpicolinamide HL-454

N-((S)-1-(((R)-1-((R)- 6,7-dimethyl-4-oxo- 1,3,6,2-dioxazaborocan- 2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-455

2,5-dichloro-N-(2-(((R)- 1-((R)-5,6-dimethyl- 4,8-dioxo-1,3,6,2- dioxazaborocan-2-yl)-3- methylbutyl)amino)-2- oxoethyl)benzamide HL-456

N-((2S,3R)-1-(((R)-1- ((R)-5,6-dimethyl-4,8- dioxo-1,3,6,2- dioxazaborocan-2-yl)-3- methylbutyl)amino)-3- hydroxy-1-oxobutan-2- yl)-6- phenylpicolinamide HL-457

N-((S)-1-(((R)-3- methyl-1-((5S,7R)- 5,6,7-trimethyl-4-oxo- 1,3,6,2-dioxazaborocan- 2-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-458

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((5S,7R)- 5,6,7-trimethyl-4-oxo- 1,3,6,2-dioxazaborocan- 2-yl)butyl)amino)-2- oxoethyl)benzamide HL-459

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((5S,7R)-5,6,7- trimethyl-4-oxo-1,3,6,2- dioxazaborocan-2- yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-460

N-((S)-1-(((R)-3- methyl-1-((5R,7R)- 5,6,7-trimethyl-4-oxo- 1,3,6,2-dioxazaborocan- 2-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-461

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((5R,7R)- 5,6,7-trimethyl-4-oxo- 1,3,6,2-dioxazaborocan- 2-yl)butyl)amino)-2- oxoethyl)benzamide HL-462

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((5R,7R)-5,6,7- trimethyl-4-oxo-1,3,6,2- dioxazaborocan-2- yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-463

N-((S)-1-(((R)-3- methyl-1-((5S,7R)- 5,6,7-trimethyl-4-oxo- 1,3,6,2-dioxazaborocan- 2-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-464

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((5S,7R)- 5,6,7-trimethyl-4-oxo- 1,3,6,2-dioxazaborocan- 2-yl)butyl)amino)-2- oxoethyl)benzamide HL-465

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((5S,7R)-5,6,7- trimethyl-4-oxo-1,3,6,2- dioxazaborocan-2- yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-466

N-((S)-1-(((R)-3- methyl-1-((5R,7R)- 5,6,7-trimethyl-4-oxo- 1,3,6,2-dioxazaborocan- 2-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-467

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((5R,7R)- 5,6,7-trimethyl-4-oxo- 1,3,6,2-dioxazaborocan- 2-yl)butyl)amino)-2- oxoethyl)benzamide HL-468

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((5R,7R)-5,6,7- trimethyl-4-oxo-1,3,6,2- dioxazaborocan-2- yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-469

N-((S)-1-(((R)-3- methyl-1-((2R,3R)- 2,3,4-trimethyl-6- oxotetrahydro-2H- 4l4,8l4- [1,3,2]oxazaborolo[2,3- b][1,3,2]oxazaborol-8- yl)butyl)amino)-1-oxo- 3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-470

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((2R,3R)- 2,3,4-trimethyl-6- oxotetrahydro-2H- 4l4,8l4- [1,3,2]oxazaborolo[2,3- b][1,3,2]oxazaborol-8- yl)butyl)amino)-2- oxoethyl)benzamide HL-471

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((2R,3R)-2,3,4- trimethyl-6- oxotetrahydro-2H- 4l4,8l4- [1,3,2]oxazaborolo[2,3- b][1,3,2]oxazaborol-8- yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-472

N-((S)-1-(((R)-3- methyl-1-((2R,3R,5S)- 2,3,4,5-tetramethyl-6- oxotetrahydro-2H- 4l4,8l4- [1,3,2]oxazaborolo[2,3- b][1,3,2]oxazaborol-8- yl)butyl)amino)-1-oxo- 3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-473

2,5-dichloro-N-(2-(((R)- 3-methyl-1- ((2R,3R,5S)-2,3,4,5- tetramethyl-6- oxotetrahydro-2H- 4l4,8l4- [1,3,2]oxazaborolo[2,3- b][1,3,2]oxazaborol-8- yl)butyl)amino)-2- oxoethyl)benzamide HL-474

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((2R,3R,5S)-2,3,4,5- tetramethyl-6- oxotetrahydro-2H- 4l4,8l4- [1,3,2]oxazaborolo[2,3- b][1,3,2]oxazaborol-8- yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-475

N-((S)-1-(((R)-1- ((2S,3R,5R)-4-ethyl- 2,3,5-trimethyl-6- oxotetrahydro-2H- 4l4,8l4- [1,3,2]oxazaborolo[2,3- b][1,3,2]oxazaborol-8- yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-476

2,5-dichloro-N-((S)-1- (((R)-1-((2S,3R,5R)-4- ethyl-2,3,5-trimethyl-6- oxotetrahydro-2H- 4l4,8l4- [1,3,2]oxazaborolo[2,3- b][1,3,2]oxazaborol-8- yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)benzamide HL-477

N-((S)-1-(((R)-1- ((2S,3R,5R)-4-ethyl- 2,3,5-trimethyl-6- oxotetrahydro-2H- 4l4,8l4- [1,3,2]oxazaborolo[2,3- b][1,3,2]oxazaborol-8- yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)-6- phenylpicolinamide HL-478

N-((S)-1-(((R)-3- methyl-1-(6-methyl-4,9- dioxo-1,3,6,2- dioxazaboronan-2- yl)butyl)amino)-1-oxo- 3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-479

(R)-2,5-dichloro-N-(2- ((3-methyl-1-(6-methyl- 4,9-dioxo-1,3,6,2- dioxazaboronan-2- yl)butyl)amino)-2- oxoethyl)benzamide HL-480

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1-(6- methyl-4,9-dioxo- 1,3,6,2-dioxazaboronan- 2-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-481

N-((S)-1-(((R)-1-((R)- 5,6-dimethyl-4,9-dioxo- 1,3,6,2-dioxazaboronan- 2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-482

2,5-dichloro-N-(2-(((R)- 1-((R)-5,6-dimethyl- 4,9-dioxo-1,3,6,2- dioxazaboronan-2-yl)- 3-methylbutyl)amino)- 2-oxoethyl)benzamide HL-483

N-((2S,3R)-1-(((R)-1- ((R)-5,6-dimethyl-4,9- dioxo-1,3,6,2- dioxazaboronan-2-yl)- 3-methylbutyl)amino)- 3-hydroxy-1-oxobutan- 2-yl)-6- phenylpicolinamide HL-484

N-((S)-1-(((R)-3- methyl-1-((5R,7S)- 5,6,7-trimethyl-4,9- dioxo-1,3,6,2- dioxazaboronan-2- yl)butyl)amino)-1-oxo- 3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-485

2,5-dichloro-N-(2-(((R)- 3-methyl-1-((5R,7S)- 5,6,7-trimethyl-4,9- dioxo-1,3,6,2- dioxazaboronan-2- yl)butyl)amino)-2- oxoethyl)benzamide HL-486

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1- ((5R,7S)-5,6,7- trimethyl-4,9-dioxo- 1,3,6,2-dioxazaboronan- 2-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-487

N-((S)-1-(((R)-1-((R)- 6,8-dimethyl-4,9-dioxo- 1,3,6,2-dioxazaboronan- 2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-488

2,5-dichloro-N-(2-(((R)- 1-((R)-6,8-dimethyl- 4,9-dioxo-1,3,6,2- dioxazaboronan-2-yl)- 3-methylbutyl)amino)- 2-oxoethyl)benzamide HL-489

N-((2S,3R)-1-(((R)-1- ((R)-6,8-dimethyl-4,9- dioxo-1,3,6,2- dioxazaboronan-2-yl)- 3-methylbutyl)amino)- 3-hydroxy-1-oxobutan- 2-yl)-6- phenylpicolinamide HL-490

N-((S)-1-(((R)-1-((S)- 6,7-dimethyl-4,9-dioxo- 1,3,6,2-dioxazaboronan- 2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-491

2,5-dichloro-N-(2-(((R)- 1-((S)-6,7-dimethyl-4,9- dioxo-1,3,6,2- dioxazaboronan-2-yl)- 3-methylbutyl)amino)- 2-oxoethyl)benzamide HL-492

N-((2S,3R)-1-(((R)-1- ((S)-6,7-dimethyl-4,9- dioxo-1,3,6,2- dioxazaboronan-2-yl)- 3-methylbutyl)amino)- 3-hydroxy-1-oxobutan- 2-yl)-6- phenylpicolinamide HL-493

N-((S)-1-(((R)-3- methyl-1-(7-methyl- 4,10-dioxo-1,3,7,2- dioxazaborecan-2- yl)butyl)amino)-1-oxo- 3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-494

(R)-2,5-dichloro-N-(2- ((3-methyl-1-(7-methyl- 4,10-dioxo-1,3,7,2- dioxazaborecan-2- yl)butyl)amino)-2- oxoethyl)benzamide HL-495

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1-(7- methyl-4,10-dioxo- 1,3,7,2-dioxazaborecan- 2-yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-496

N-((S)-1-(((R)-1-((R)- 6,7-dimethyl-4,10- dioxo-1,3,7,2- dioxazaborecan-2-yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-497

2,5-dichloro-N-(2-(((R)- 1-((R)-6,7-dimethyl- 4,10-dioxo-1,3,7,2- dioxazaborecan-2-yl)-3- methylbutyl)amino)-2- oxoethyl)benzamide HL-498

N-((2S,3R)-1-(((R)-1- ((R)-6,7-dimethyl-4,10- dioxo-1,3,7,2- dioxazaborecan-2-yl)-3- methylbutyl)amino)-3- hydroxy-1-oxobutan-2- yl)-6- phenylpicolinamide HL-499

N-((S)-1-(((R)-3- methyl-1-(7-methyl-4- oxo-1,3,7,2- dioxazaborecan-2- yl)butyl)amino)-1-oxo- 3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-500

(R)-2,5-dichloro-N-(2- ((3-methyl-1-(7-methyl- 4-oxo-1,3,7,2- dioxazaborecan-2- yl)butyl)amino)-2- oxoethyl)benzamide HL-501

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1-(7- methyl-4-oxo-1,3,7,2- dioxazaborecan-2- yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-502

N-((S)-1-(((R)-3- methyl-1-(7-methyl- 1,3,7,2-dioxazaborecan- 2-yl)butyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-503

(R)-2,5-dichloro-N-(2- ((3-methyl-1-(7-methyl- 1,3,7,2-dioxazaborecan- 2-yl)butyl)amino)-2- oxoethyl)benzamide HL-504

N-((2S,3R)-3-hydroxy- 1-(((R)-3-methyl-1-(7- methyl-1,3,7,2- dioxazaborecan-2- yl)butyl)amino)-1- oxobutan-2-yl)-6- phenylpicolinamide HL-505

N-((S)-1-(((R)-1-(4- ethyltetrahydro-2H- 4l4,8l4- [1,3,2]oxazaborolo[2,3- b][1,3,2]oxazaborol-8- yl)-3- methylbutyl)amino)-1- oxo-3-phenylpropan-2- yl)pyrazine-2- carboxamide HL-506

(R)-2,5-dichloro-N-(2- ((1-(4-ethyltetrahydro- 2H-4l4,8l4- [1,3,2]oxazaborolo[2,3- b][1,3,2]oxazaborol-8- yl)-3- methylbutyl)amino)-2- oxoethyl)benzamide HL-507

N-((2S,3R)-1-(((R)-1- (4-ethyltetrahydro-2H- 4l4,8l4- [1,3,2]oxazaborolo[2,3- b][1,3,2]oxazaborol-8- yl)-3- methylbutyl)amino)-3- hydroxy-1-oxobutan-2- yl)-6- phenylpicolinamide Stability Study

Compounds were tested for their stability, under three different conditions (see Table 2), by the following procedures:

-   -   1. Room Temperature and Dry: compounds were left at the room         temperature (20° C.) under inert dry gas;     -   2. 30° C. and 65% Humidity: compounds sealed with double bags         were put into a stability chamber. Temperature was set at 30° C.         while the humidity was controlled at 65%.     -   3. 37° C. pH=7.4 solution: compounds were dissolved in PBS         solution and then the entire solution was submerged under a         37° C. water bath.

TABLE 2 Stability study of designed chiral specific boron derivatives. Room Temp 30° C./ 37° C. H₂O/ Compound Dry 65% Humidity pH 7.4 HL01-0 − HL01-11 + + + HL01-15 + + + HL01-17 + − Decompose Instant Note: “+” meaning stable, “−” meaning quickly degradable, as determined by RP-HPLC. Cell Viability Assay 1. Cell Line

The multiple myeloma cell line MM1.S was obtained from the ATCC. Cells were cultured in standard RPMI-1640 media (Hyclone) supplemented with 10% heat-inactivated fetal bovine serum (Gibco), 1% penicillin/streptomycin (Gibco) and grown in a humidified incubator with 5% CO₂ at 37° C.

Eight thousand MM1.S cells per well were seeded in tissue culture-treated 96-well plate (Nunc) and incubated overnight.

2. Compound Treatment

Eighteen hours after seeding, MM1.S cells were treated with a series of concentrations of five different compounds (Bortezomib, HL01-01, HL01-11, HL01-15, HL1-147) or DMSO vehicle control for 72 hrs in a humidified incubator with 5% CO₂, at 37° C. The concentrations of five different compounds were 0.3, 1, 3.16, 10, 31.6, 100, 316, and 1000 nM. Each well had the same DMSO concentration of 0.05%.

3. Cell Viability Assay (MTS Assay)

The effects of compounds on cell viability were assessed using CellTiter 96®A Queous One solution Reagent (Promega; G3580).

After being treated with various compounds for 72 hrs, cells in the 96-well plate were centrifuged 1000 rpm for 3 minutes, and 180 ul supernatant were removed from each well. Cells were incubated with 20 ul CellTiter 96®A Queous One solution Reagent and put into incubator with 5% CO₂, at 37° C. for an additional 4 hrs. The absorbance was measured at 490 nm with Automatic Microplate reader (Infinite M1000 pro, Tecan). There was a liner relationship (r²=0.99) between absorbance and cell number in each plate format. Four sets of experiments for each drug combinations were carried out. Cell viability (Percentage of Cell Survival) was calculated by the following formula: cell viability (%)=(average absorbance of treated group-average absorbance of blank)/(average absorbance of untreated group−average absorbance of blank)×100%. IC50 values were calculated using Prism software.

Results

The cytotoxic effects of compounds including Bortezomib, HL01-11, and HL01-15 on MM1.S cell were assessed using the MTS assay. It was found that all compounds could dose-dependently decrease the cell viability in MM1.S cell. As represented by the cell line assay shown in FIG. 1. Bortezomib and HL01-11 exhibited strong cytotoxic effects on MM1.S cells and both compounds had similar IC₅₀ values nearly 2 nM. The effect of HL01-15 was weaker than the other compounds. The IC₅₀ value of HL01-15 was 6.85 nM, as set forth in Table 3:

TABLE 3 Compound IC₅₀ (nM) Bortezomib 1.76 HL01-01 1.96 HL01-11 1.62 HL01-15 6.85 HL01-17 (Ixazomib) 9.45

Five compounds exhibited cytotoxicity in MM1.S cells. MM1.S cells were treated with various concentrations of Bortezomib, HL01-11, and HL01-15 for 72 h. Cell viability was assessed using the MTS assay. Mean SEM (n=4).

Although the disclosure has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims. 

What is claimed is:
 1. A compound represented by the following formula:

or a pharmaceutically acceptable salt thereof.
 2. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, a diluent, or an excipient.
 3. A method of treating multiple myeloma in a human in need thereof, comprising administering to said human an effective amount of a compound of claim 1 or a pharmaceutically acceptable acid addition salt thereof.
 4. A compound represented by the following formula:

or a pharmaceutically acceptable salt thereof.
 5. A pharmaceutical composition comprising a compound of claim 4 or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, a diluent, or an excipient.
 6. A method of treating multiple myeloma in a human in need thereof, comprising administering to said human an effective amount of a compound of claim 4 or a pharmaceutically acceptable acid addition salt thereof. 